In vitro and in vivo modeling of gliomagenesis based on the IDH1R132H mutation by Fischer, Viktoria
Aus dem Institut für Pathologie der Universität Heidelberg 
Abteilung für Neuropathologie 
und 
Klinische Kooperationseinheit Neuropathologie 
Deutsches Krebsforschungszentrum  
(Direktor: Prof. Dr. med. Andreas von Deimling) 
 
 
 
 
 
In vitro and in vivo modeling of gliomagenesis based 
on the Idh1R132H mutation 
 
 
 
 
Inauguraldissertation 
zur Erlangung des Doctor scientiarum humanarum (Dr.sc.hum.) 
an der 
Medizinischen Fakultät Heidelberg 
der 
Ruprecht-Karls-Universität 
 
 
 
 
 
 
 
 
 
vorgelegt von 
 
Viktoria Fischer 
 
aus 
Bochum 
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dekan: Prof. Dr. med. Wolfgang Herzog  
 
Doktorvater: Prof. Dr. med. Andreas von Deimling
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Meiner Familie
 List of Abbreviations 
 
2-HG    2-hydroxyglutarate 
4-OHT   4-hydroxytamoxifen 
5hmC    5-hydroxymethylcytosine 
5mC    5-methylcytosine 
ALT    alternative lengthening of telomeres phenotype 
AML    acute myeloid leukemia 
AT    annealing temperature 
ATP    adenosine triphosphate 
ATRX    alpha-thalassemia/mental retardation syndrome X-linked 
BCA    bicinchoninic acid      
CIC    capicua transcriptional repressor, human 
Cic    capicua transcriptional repressor, murine 
clC    cleaved caspase 
clPARP   cleaved Poly (ADP) Ribose Polymerase 
CreERT2 cyclization recombination fused to hormone binding domain of 
a modified estrogen receptor 
CT    computed tomography 
CTB    Cell Titer Blue Cell Viability Assay 
CTG3D   Cell Titer-Glo3D Cell Viability Assay 
ES    embryonic stem cell 
ET    elongation time 
FMZ    18F-flumazenil 
FDG    18F-fluorodeoxyglucose 
FFPE    formalin fixed paraffin embedded tissue 
Flp    flippase, recombinase 
Foxn1    forkhead box protein N1, murine 
FRT    flippase recognition target cassette 
FUBP1   far upstream element binding protein 1 
G-CIMP   CpG island methylator phenotype 
GBM    glioblastoma 
GFP    green fluorescent protein 
HE    haematoxilin eosin staining 
HGDH   D- and L-2-HG dehydrogenase 
HRP    horseradish peroxidase 
IDH1    isocitrate dehydrogenase, human 
Idh1    isocitrate dehydrogenase, murine 
iEEG    intracranial elektroencephalogram  
JmjC    Jumonji C domain 
Ki-67    antigen Ki-67 
LOH    loss of heterozygosity 
MALDI-TOF   Matrix Assisted Laser Desorption Ionization - Time of Flight 
MEG    magnetoencephalography
 MES    2-(N-morpholino)ethansulfonsäure 
MHC    major histocompatibility complex 
MOPS    3-(N-morpholino)propansulfonsäure 
MRI    magnetic resonance imaging 
NAD    nicotinamide adenine dinucleotide 
NADH   nicotinamide adenine dinucleotide, reduced 
NADP    nicotinamide adenine dinucleotide phosphate 
NADPH   nicotinamide adenine dinucleotide phosphate, reduced 
NCH    Neurochirurgie Heidelberg 
NMDA   N-methyl-D-aspartate receptor 
NP40    nonidet-P40  
NSC    neural stem cell 
p53    protein 53 
PBS    phosphate buffered saline 
PCA    perchloric acid 
PDD    papain dispase DNase   
PET    positron emission tomography 
pHH3    phospho histone H3 
pTERT    promoter TERT mutation 
ROS    reactive oxygen species 
rpm    revolutions per minute 
SDS    sodium dodecyl sulfate 
SDS-PAGE   sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SLC7AI   cysteine-glutamate antiporter xCT 
SUV    PET CT standard uptake value 
TBS-T    tris-buffered saline (with Tween) 
TERT    telomerase reverse transcriptase  
TET    ten-eleven translocation methylcytosine dioxygenase 
TP53    tumor protein 53, gene 
a-KG    alpha-ketoglutarate 
gH2AX   phosphorylated histone 2AX 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table of contents 
 
	8	
  
Table of contents 
 
	 9	
Table of contents 
Table of contents ...................................................................................................................... 9 
1 Introduction .................................................................................................................... 11 
1.1 Diffuse gliomas .................................................................................................................... 11 
1.2 Grading of tumors of the central nervous system ........................................................... 11 
1.3 Molecular markers ............................................................................................................. 12 
1.4 Isocitrate dehydrogenases (IDHs) ..................................................................................... 13 
1.4.1 The “oncometabolite” 2-HG ......................................................................................... 15 
1.4.2 Clinical features of IDH-mutant glioma ...................................................................... 17 
1.4.3 Mutant IDH1 as therapeutic target .............................................................................. 20 
1.5 IDH1 and secondary alterations in gliomagenesis ........................................................... 21 
1.5.1 Association of IDH mutations with TP53 and ATRX mutations in astrocytoma ..... 23 
1.5.2 Association of IDH mutations with 1p/19q co-deletions in oligodendroglioma ....... 23 
1.6 Aims of the study ................................................................................................................ 24 
2 Materials & Methods ..................................................................................................... 26 
2.1 Matings of mice with different conditional alleles ........................................................... 26 
2.2 Generation of Cic flox mice ............................................................................................... 26 
2.3 Chemicals ............................................................................................................................ 27 
2.4 Genotyping .......................................................................................................................... 27 
2.5 Preparation of neural stem cells ........................................................................................ 28 
2.6 Passaging and induction of genetic alterations ................................................................ 29 
2.7 Proliferation assay .............................................................................................................. 30 
2.8 SDS-Page and Western blot ............................................................................................... 30 
2.9 Reverse transcription PCR ................................................................................................ 33 
2.10 Soft agar assay .................................................................................................................... 34 
2.11 2-HG assay .......................................................................................................................... 35 
2.12 Dotblot ................................................................................................................................. 37 
2.13 Histology of neurospheres .................................................................................................. 37 
2.14 Immunohistochemistry ...................................................................................................... 38 
2.15 Intracranial injections of neural stem cells ...................................................................... 39 
2.16 Imaging and analysis .......................................................................................................... 41 
3 Results ............................................................................................................................. 44 
3.1 Generation of Cic flox mice ............................................................................................... 44 
3.2 Generation of neural stem cells with different genetic alterations ................................ 44 
3.2.1 Induction of genetic alterations and validation of established cell lines ................... 45 
3.3 Functional characterization of Idh1R132H p53-/- NSCs: short-term effects ..................... 47 
3.3.1 Cell viability .................................................................................................................... 47 
3.3.2 Colony formation in soft agar ....................................................................................... 49 
3.3.3 Analysis of apoptotic proteins ....................................................................................... 50 
3.3.4 Production of 2-HG ........................................................................................................ 51 
3.4 In vivo allograft model ....................................................................................................... 51 
3.4.1 Intracranial injections ................................................................................................... 52 
3.4.2 General problems with immunodeficient mice during the time of the experiment . 52 
3.5 Functional characterization of Idh1R132H p53-/- NSCs: long-term effects ....................... 53 
3.5.1 Cell viability .................................................................................................................... 53 
3.5.2 Colony formation in soft agar ....................................................................................... 54 
3.5.3 Analysis of apoptotic proteins ....................................................................................... 55 
3.5.4 Analysis of cell cycle markers in long-term cells ......................................................... 56 
3.5.5 Analysis of epigenetic effects of Idh1R132H .................................................................... 57 
3.5.6 Production of 2-HG ........................................................................................................ 58 
3.6 Loss of Idh1R132H in long-term cell lines ............................................................................ 59 
3.6.1 Loss of Idh1R132H in vivo? ............................................................................................... 61 
3.7 MRI monitoring of BALB/c nude mice after intracranial injections ............................ 62 
Table of contents 
 
	10	
3.7.1 9.4 T scans ....................................................................................................................... 64 
3.8 Immunohistochemistry ...................................................................................................... 65 
3.9 In vitro analysis of a Cic knock-out alone and in an Idh1R132H background .................. 68 
3.9.1 Cell viability .................................................................................................................... 68 
3.9.2 Colony formation in soft agar ....................................................................................... 70 
3.9.3 Effects on epigenetics ..................................................................................................... 70 
3.9.4 Production of 2-HG ........................................................................................................ 71 
3.10 PET imaging: IDH1R132H and its relation to epileptogenesis ........................................... 72 
4 Discussion ....................................................................................................................... 76 
4.1 Effects of Idh1R132H ............................................................................................................. 77 
4.2 The difference between short- and long-term inductions ............................................... 80 
4.3 Loss of Idh1R132H in vitro ..................................................................................................... 84 
4.4 Migration of induced NSCs in vivo ................................................................................... 85 
4.5 Cell type ............................................................................................................................... 86 
4.6 Additional mutation ........................................................................................................... 87 
4.7 Genetic background of mice .............................................................................................. 87 
4.8 Detection of implanted cells ............................................................................................... 88 
4.9 Implementation of Cic-/-  in an Idh1R132H background ..................................................... 89 
4.10 Functional neuroimaging of glioma xenografts with IDH1R132H mutation .................... 91 
5 Summary ......................................................................................................................... 93 
6 Zusammenfassung ......................................................................................................... 94 
7 References ....................................................................................................................... 96 
8 Supplement ................................................................................................................... 110 
9 Acknowledgements ...................................................................................................... 115 
Publications .......................................................................................................................... 119 
Eidesstattliche Versicherung ............................................................................................... 121 
 
 
 
  
Introduction 
 
	 11	
1 Introduction 
 
Brain tumors, especially gliomas, are a disease that cannot be cured with the current methods, 
although different treatment strategies are available. This could be a consequence of missing 
glioma models. To understand how these tumors arise and how they can be tackled, it is of 
utmost importance to develop a defined model mimicking the genetic features of human 
glioma.  
	
1.1 Diffuse gliomas 
Gliomas are the most frequent intrinsic tumor of the central nervous system. They can be 
divided into diffuse and non-diffuse gliomas that show a more circumscribed growth pattern. 
The diverse gliomas are classified according to their microscopic similarities with putative 
cells of origin along glial precursor cell lineages (Wesseling and Capper, 2017). This work 
focusses on diffuse gliomas, which are characterized by an extensive infiltrative growth into 
the surrounding CNS parenchyma.  
 
1.2 Grading of tumors of the central nervous system 
The classification of brain tumors has been based on the idea that tumors can be distinguished 
by histological differences in combination with potential cells of origin and their levels of 
differentiation for nearly one century. The pioneering work by Bailey and Cushing in 1926 
first described the association between histology and prognosis (Bailey and Cushing, 1926). 
The WHO classifications of 2000 and 2007 started to combine the histological features with 
genetic differences between different tumor entities. During the last years and especially since 
the last update, the WHO classification of 2016, well-established molecular parameters are 
incorporated into the classification of diffuse gliomas (Louis et al., 2016b).  
 
Histological grading of diffuse gliomas and the respective malignancy grade (WHO grade II, 
III or IV) is based on the presence or absence of mitotic activity, nuclear pleomorphism, 
cellularity, necrosis and florid microvascular proliferation. The histological grading combined 
with genetic alterations, clinical findings (e.g. patient age, tumor location, etc), radiological 
features (e.g. contrast enhancement), surgical resection and proliferation index values, gives 
an indication on the response to therapy and outcome. The genetic profile has become 
increasingly important, as some genetic alterations have important prognostic implications. 
One example is the presence of an isocitrate dehydrogenase 1 (IDH1) mutation in diffuse 
gliomas that contributes to the overall estimate of prognosis. In previous classifications, all 
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astrocytic tumors were grouped together. Nowadays all diffusely infiltrating gliomas (whether 
astrocytic or oligodendroglial) are classified based on their growth pattern, their behavior and 
their IDH1 mutational status. According to the new classification, diffuse gliomas include 
WHO grade II and III astrocytic tumors, the grade II and III oligodendrogliomas, the grade IV 
glioblastomas (GBMs) and the related and partly unspecified gliomas, as for example those of 
childhood (Figure 1) (Louis et al., 2016a; Louis et al., 2016b; Wesseling and Capper, 2017). 
 
 
Figure 1. Summary of the WHO classification of brain tumors 2016. Diagram showing a 
simplified algorithm for classification of diffuse gliomas based on a combination of 
histological and genetic features, according to the WHO CNS classification 2016. The 
diagnosis does not necessarily proceed from histology first to molecular genetic features 
afterwards, because molecular signatures sometimes outweigh histological characteristics 
(Louis et al., 2016b). (NOS = not otherwise specified). 
 
1.3 Molecular markers 
Extensive research provided methods to unravel the status of the whole cancer genome. These 
methods include whole genome sequencing, whole exome sequencing, mRNA sequencing 
and expression profiling. Application of these methods provided a large landscape of genomic 
alterations in diffuse gliomas. As an example, whole exome sequencing revealed on average 
16 somatic mutations in astrocytomas, 36 in anaplastic astrocytomas and 46-50 in GBMs 
(Killela et al., 2014). However, only a few of these genetic alterations are practically useful in 
classifying diffuse gliomas. These genetic alterations have to be detected at significant 
frequencies, have to draw clear lines to divide subgroups and these subgroups should be 
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associated with clinically significant features. The few genetic alterations fulfilling these 
criteria are hypothesized to be those that are involved in gliomagenesis. These alterations are 
mainly observed in lower grade gliomas, in contrast to those that play important roles during 
progression (Otani et al., 2017). Among the key genetic alterations that are important for the 
molecular classification of diffuse gliomas are IDH1/2 mutations. These are often 
accompanied by different other alterations, which will be explained in the following. 
 
1.4 Isocitrate dehydrogenases (IDHs) 
Mutations in the isocitrate dehydrogenases type 1 and 2 (IDH1/2) were first described in large 
subsets of gliomas in 2008 (Balss et al., 2008; Parsons et al., 2008). Before that, only one 
study in 2006 had reported on a single IDH1R132C mutation in a cohort of eleven colorectal 
cancer samples (Sjoblom et al., 2006). After 2008, the number of publications on IDH 
mutations and cancer has strongly increased. In the initiating study, 22 human GBM samples 
were screened for about 20,000 protein coding genes, from which five patients carried the 
highly specific point mutation IDH1R132H (Parsons et al., 2008). Further studies showed that 
more than 70% of diffuse grade II and III gliomas and secondary GBMs display mutations in 
the IDH1 gene (Balss et al., 2008; Watanabe et al., 2009; Yan et al., 2009). 
 
IDH1/2 mutations occur in different seemingly unrelated neoplasms such as gliomas, acute 
myeloid leukemia (AML), chondrosarcomas and cholangiocarcinomas (Amary et al., 2011a; 
Mardis et al., 2009; Wang et al., 2013). In gliomas, IDH1/2 mutations generally occur in 
younger adults (20-60 years) and are more common in grade II and III astrocytomas and 
oligodendrogliomas compared to GBMs (Bleeker et al., 2009; Parsons et al., 2008; Yan et al., 
2009). GBMs that arose from lower grade gliomas are called secondary glioblastomas. About 
60-80% of these secondary GBMs exhibit a mutation. In contrast, de novo primary GBMs 
mostly do not have this mutation (Toedt et al., 2011; Watanabe et al., 2009; Yan et al., 2009). 
More than 90% of the mutations involve IDH1 and about 90% of these mutations are 
transitions of CGT to CAT in codon 132, resulting in a replacement of the arginine residue 
with a histidine (IDH1R132H). There are also other point mutations at codon 132, resulting in 
different amino acid substitutions. In IDH2 mutations homologous to those in IDH1 occur in 
R172 (Ward et al., 2010). IDH1/2 mutations occur always heterozygously, by which the 
tumor always retains one wild type copy of the gene.  
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IDH1 occurs in the cytosol and peroxisomes and is encoded by the IDH1 gene on 
chromosome 2q. It catalyzes the reversible oxidative decarboxylation of isocitrate to a-
ketoglutarate (a-KG) thereby reducing NADP+ to NADPH. The same reaction is catalyzed in 
mitochondria by IDH2, encoded by the IDH2 gene on chromosome 15q (Stoddard et al., 
1993). Both enzymes function as homodimers and are important for cellular defense against 
oxidative damage and in the regulation of a-KG dependent dioxygenases (Hausinger, 2004; 
Jo et al., 2002; Lee et al., 2004; Lee et al., 2002). In contrast, IDH3, functions as a 
heterotetramer in the tricarboxylic acid cycle. It catalyzes the irreversible conversion of 
isocitrate to a-KG producing of NADH (Figure 2) (Ramachandran and Colman, 1980). There 
appear to be no glioma specific mutations in the subunits of IDH3 (Krell et al., 2011). 
 
 
Figure 2. Overview about the cellular locations and function of IDH1, IDH2 and IDH3. 
IDH1 and IDH2 are homodimers whereas IDH3 appears as a heterotetramer, consisting of 
different subunits. All of the three enzymes oxidize isocitrate to a-KG. IDH1 and IDH2 use 
NADP+ as a cofactor and generate NADPH. In contrast, IDH3 utilizes NAD+ and produces 
NADH. IDH1 is located in the cytosol and also peroxisomes, whereas IDH2 and IDH3 appear 
in mitochondria. In general, IDH1 and IDH2 can convert a-KG back to isocitrate, but IDH3 
works unidirectional only (Horbinski, 2013). (IDH = isocitrate dehydrogenase; ISO = 
isocitrate; a-KG = a-ketoglutarate) 
 
IDH1/2 mutations always occur in the catalytic domain, targeting codons of essential 
argenins. This implies a mechanism of dominant inhibition or gain-of-function. Actually, both 
scenarios are reality. It could be shown that the R132H point mutation results in both, a loss 
of function and in a gain of a neoenzymatic activity of IDH1 (Dang et al., 2010). Mutant 
IDH1 enzyme prefers to bind and reduce a-KG to D-2-hydroxyglutarate (2-HG), consuming 
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NADPH. It does not longer bind isocitrate and decarboxylates it to a-KG. Subsequently, it 
was shown that mutant gliomas have multi-fold elevated levels of 2-HG compared to their 
wildtype counterparts, with tissue concentrations of 10-30 mM. 2-HG production was also 
measured in other cancer types with different IDH1 and IDH2 mutations (Amary et al., 
2011b; Borger et al., 2012; Gross et al., 2010; Sellner et al., 2010; Ward et al., 2012; Ward et 
al., 2010). Although all IDH1/2-mutant tumors produce 2-HG, the production varies 
dependent on the type of the mutation. The R132H type of IDH1 and R172 of IDH2 are the 
weakest 2-HG producers (Jin et al., 2011). There appears to be an inverse correlation of the 
type of IDH1R132 mutation with the amount of 2-HG produced (Pusch et al., 2014). Thus, 
different types of IDH1/2 mutations appear in different types of tumors with the respective 
production of 2-HG. As an example, there is a strong IDH1R132H preponderance in gliomas, 
whereas AMLs more likely harbor an IDH2 mutation (Abbas et al., 2010). In gliomas, when 
the R132C variant of IDH1 could be detected, it tends to be found in astrocytoma, whereas 
mutations of IDH2 appear more often in grade III oligodendroglioma (Hartmann et al., 2009). 
These findings support the assumption that the amount of 2-HG produced depends on the 
tumor site, but might also somehow affect which kind of tumor is formed. In contrast to 
IDH1/2 mutations, up until today no cancer-associated mutations of IDH3 were described, 
probably because it might be difficult to gain a neoenzymatic function in a heterotetrameric 
complex via a single point mutation (Krell et al., 2011). 
 
1.4.1 The “oncometabolite” 2-HG 
The dicarboxylic acid 2-HG has a chiral center and therefore two different enantiomers, (R)-
2-HG and (S)-2-HG exist, which are also termed D- and L-2-HG (Figure 3). Both are 
unwanted byproducts of mitochondrial metabolism, with intracellular levels below 0.1 µM 
(Kranendijk et al., 2012). D- and L-2-HG dehydrogenase (HGDH), catalyze the reaction of 2-
HG to a-KG and are thus responsible to keep the concentration of 2-HG on this low level.  
 
Figure 3. The two stereoisomers of 2-HG. Depiction of the two stereoisomeric forms of 2-
HG, called S- and R-enantiomers, also denoted L and D isomer. 
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Prior to the studies on 2-HG, studies mostly focused on the metabolic disease 2-
hydroxyglutaric aciduria. The disease is either caused by a deficiency in one of the two 
HGDH enzymes, resulting in an accumulation of the respective 2-HG, or by an IDH mutation. 
The later was detected in some cases with elevated 2-HG levels, but without a mutation in the 
HGDH genes, after the IDH mutations were described in tumors. In contrast, HGDH 
mutations do not occur in glioma (Brehmer et al., 2011; Krell et al., 2011). Patients suffering 
from D-2-HG aciduria suffer from encephalopathy with cardiomyopathy and dysmorphisms 
as well as developmental delay and hypotonia (Struys, 2006). L-2-HG aciduria patients were 
found to develop brain tumors, seizures and leukoencephalopathy (Steenweg et al., 2010). 
IDH mutated tumors only produce the D-2-HG type isomer (Choi et al., 2012; Dang et al., 
2010). It was shown that mutant cells secrete 2-HG into the extracellular space in vitro and in 
vivo, which might suggest that 2-HG also affects surrounding non-neoplastic cells (Dang et 
al., 2010; Fathi et al., 2012). Amongst others, the diverse effects of 2-HG are the generation 
of elevated ROS levels, inhibition of cytochrome c oxidase and ATP synthase and a lower 
rate of aerobic glycolysis (Latini et al., 2005; Latini et al., 2003). 2-HG blocks prolyl-
hydroxylation of collagen that influences collagen maturation and finally leads to basement 
membrane aberrations (Sasaki et al., 2012). However, various studies conducted during the 
last years implicate the epigenome as a critical target of 2-HG in cancer. 
 
Histone methylation is a process of epigenetic control, whereby methyl groups are added to 
specific amino acid residues of histone proteins. This process regulates the chromatin state. 
These modifications affect e.g. genomic imprinting, DNA repair and gene expression (Tian 
and Fang, 2007). The metabolite 2-HG was found to inhibit a-KG-dependent Jumonji C 
(JmjC) domain-containing histone demethylases, such as JHDM1A, JMJD2A and JMJD2C, 
by competing with a-KG (Chowdhury et al., 2011; Lu et al., 2012; Xu et al., 2011). In line 
with the inhibition of these demethylases, methylation of H3K9, H3K27 and H3K36 is 
increased when IDH1/2 mutations are present (Lu et al., 2012). In addition to blocking 
histone demethylases, 2-HG is also able to inhibit TET1/2 methylcytosine hydroxylases, 
which is important for DNA demethylation (Chowdhury et al., 2011; Figueroa et al., 2010; 
Xu et al., 2011). Inhibition of DNA demethylation promotes global hypermethylation, 
influencing global gene expression (Figure 4). This phenomenon is commonly seen in 
neoplasms with IDH1/2 mutations (Turcan et al., 2012; Xu et al., 2011). The glioma CpG 
island methylator phenotype (G-CIMP) describes this phenomenon in glioma (Noushmehr et 
al., 2010). 2-HG alters global histone and DNA methylation promoting epigenetic rewiring, 
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which might promote tumorigenesis. Although 2-HG is often called oncometabolite, it is 
believed that the presence of 2-HG alone is not sufficient to induce gliomagenesis. Given the 
fact that 2-HG can inhibit cellular differentiation, mutant IDH1/2 might not be sufficient to 
induce an infiltrating, tumorigenic phenotype (Lu et al., 2012). It rather creates an 
environment extending the opportunity for further tumor promoting mutations to occur in 
undifferentiated cells. 
 
Figure 4. Production of 2-HG by mutant IDH1 alters gene expression. 2-HG produced 
from mutant IDH1 inhibits Jumonji C (JmjC) domain histone demethylases and 
methylcytosine hydroxylases (TET1/2). This leads to an increase of histone methylation and 
DNA hypermethylation. These alterations induced by IDH1 are proposed to increase 
proliferation accompanied by a decrease of cellular differentiation, which might be important 
during tumorigenesis. 
 
1.4.2 Clinical features of IDH-mutant glioma 
Tumors harboring an IDH mutation are preferentially located in the frontal lobes compared to 
IDH wild-type glioma. During imaging, IDH-mutant tumors do take up less contrast 
enhancing agent, except for the case that they are recurrent or of higher grade (Beiko et al., 
2014). This might be explained by the fact that the blood-brain barrier is more intact 
compared to patients with an IDH wild-type tumor. 
 
IDH1R132H and epilepsy 
One of the initial symptoms in patients suffering from low-grade glioma is the occurrence of 
epileptic seizures (Chang et al., 2008; van Breemen et al., 2007). The frequency of seizures 
depends on histology as well as tumor grading and location. It was shown that patients with 
low-grade temporal, insular or frontal tumors have a predisposition to develop seizures 
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(Chang et al., 2008; Stockhammer et al., 2012). Seizure burden of glioma patients constitutes 
a major problem as it impacts cognitive function and decreases their quality of life (Klein et 
al., 2003). Accordingly, there is a definite need to better understand epileptogenesis in a 
glioma background. Furthermore, there is an increasing number of studies describing the 
relation of seizure occurrence and a concomitant IDH1R132H mutation (Chen et al., 2017b; 
Feyissa et al., 2018; Kerkhof et al., 2015; Li et al., 2018; Neal et al., 2018; Toledo et al., 
2017). Interestingly, seizures are not only a symptom of IDH mutant glioma but also occur in 
the metabolic disease L-2-HG aciduria, suggesting that 2-HG might impact epileptogenesis 
(Steenweg et al., 2010; Stockhammer et al., 2012). As 2-HG is secreted into the culture 
medium in vitro and the extracellular space in vivo, it might influence the surrounding non-
neoplastic cells (Dang et al., 2010; Fathi et al., 2012). Additionally, 2-HG has a structural 
similarity with glutamate, which means that it might also bind to NMDA receptors. 
NR1/NR2A NMDA receptors are activated by 2-HG, examined in neuronal cultures (Kolker 
et al., 2002). In line with this, it was found that there is an increased expression of NMDA 
receptors in the tumor area, consisting of NR1, NR2A and NR2B subunits, which is also the 
area of seizure initiation (Kohling et al., 2006; Shamji et al., 2009).These findings suggest 
that seizures in patients with an IDH-mutant glioma are not initiated due to tumor infiltration 
or mass effects, but rather points towards a direct effect of the extracellular 2-HG on the 
surrounding cells. However, little is known about this relation in patients yet, which might be 
examined by use of for example specific radio tracers that can be applied during imaging. 
Functional neuroimaging with positron emission tomography (PET) is commonly used as a 
tool for presurgical investigation of epileptic foci (von Oertzen, 2017). One of the well-known 
radiotracers is 18F-fluorodeoxyglucose (FDG) to image glucose metabolism. It was shown that 
metabolic activity for glucose might be decreased in regions extending beyond the seizure 
onset zone until the contralateral hemisphere. Further, the severity of the seizure was 
correlated with a larger extent of hypometabolism (Hashiguchi et al., 2007; Vinton et al., 
2007; Wong et al., 2010). Propagation of interictal epileptic activity recorded by 
magnetoencephalography (MEG) determined with voxel by voxel analysis, corresponds to a 
reduced hypometabolism area detected in FDG-PET (Shibata et al., 2017). 
 
Detection 
Although the understanding of IDH1/2 mutations is incomplete, there is an urgent need in 
screening for their presence in the context of glioma classification according to the last WHO 
update described above. In addition, several glioma-mimicking diseases were shown not to be 
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associated with an IDH mutation, rendering this marker even more useful (Capper et al., 
2011). Due to the high frequency and discriminative power of the IDH1R132H mutation, 
extensive research was done to develop a mutation-specific monoclonal antibody for reliable 
detection on immunohistochemical samples (Capper et al., 2010; Capper et al., 2009). Even 
in biopsies with only a low number of glioma cells next to non-neoplastic tissue, the antibody 
reliably detects mutated cells (Sahm et al., 2012a). Although this antibody is an excellent tool 
for the detection of IDH1R132H in samples, it cannot screen for rare IDH1 as well as IDH2 
mutations. Thus, follow-up testing of immunonegative cases with methods such as PCR and 
Sanger sequencing is necessary. It was also shown that the high levels of 2-HG released by 
the tumor can serve as a biomarker detectable with an enzymatic assay from brain tumor 
biopsies or serum of AML patients (Balss et al., 2012). Compared to standard detection 
methods such as mass spectrometry or magnetic resonance spectroscopy, this assay seems to 
be more sensitive and has cost and time advantages (Choi et al., 2012; Sahm et al., 2012b). 
 
Prognosis 
Tumors with an IDH mutation are less aggressive compared to their WHO grade-matched 
wild-type counterparts (Nobusawa et al., 2009; Parsons et al., 2008; Sanson et al., 2009; Yan 
et al., 2009). This is due to a large proportion of IDH wild-type astrocytomas representing 
underdiagnosed glioblastomas (Hasselblatt et al., 2018). In contrast to grade III-IV IDH 
mutated tumors, grade III tumors lacking the mutations behave in the same aggressive way as 
wild-type grade IV tumors (Yan et al., 2009). Moreover, patients harboring an IDH mutation 
are in general younger and have a better prognosis for survival (Hartmann et al., 2010; Olar et 
al., 2015). As an example, in the study of Olar et al. 558 grade II and III gliomas were 
analyzed and it was reported that the median survival of patients with an IDH mutation is 
12.41 years (grade II) and 13.35 years (grade III), whereas it was only 4.82 years (grade II) 
and 1.97 years (grade III) for wild-type tumors (Olar et al., 2015). Overall survival in patients 
with GBM harboring an IDH mutation (three years) versus non-mutated tumor (one year) is 
even worse (Hartmann et al., 2010). Given the fact that 2-HG is believed to be an 
oncometabolite, it contradicts the survival benefit of patients harboring an IDH mutation. This 
could be explained by the lower median age of patients with the mutation and the concomitant 
metabolic changes leading to an enhanced chemo- and radiosensitive environment supporting 
effective treatment against these tumors (Houillier et al., 2010). Meanwhile the classification 
of glioma underwent major changes and IDH mutations are now an essential diagnostic 
marker by which the tumors are distinguished (Louis et al., 2016b). Based on this work, 
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tumors with and without IDH mutations are not compared to each other anymore because they 
are different entities.  
 
 
Figure 5. Kaplan-Meier estimate from a study of 558 pooled grade II and III diffuse 
gliomas. Discriminating between IDH wild-type and IDH mutated tumors shows a better 
overall survival in case of tumors with IDH mutation (Olar et al., 2015). 
 
1.4.3 Mutant IDH1 as therapeutic target 
The high frequency and the fact that the IDH mutations appear in multiple tumor entities, 
provide a likely approach for targeted cancer therapy. Suppression of mutant IDH1 with a 
concomitant decrease in 2-HG led to inhibition of proliferation and a decrease of the 
clonogenic potential (Jin et al., 2012). These data suggest that mutant IDH1 might be a valid 
therapeutic target. 
 
Indeed, intensive research about IDH1 led to the development of inhibitors as for example 
BAY 1436032. This inhibitor was recently described as a pan-inhibitor that reduces 2-HG 
levels in cells carrying different IDH1 codon 132 mutations. Orally administered BAY 
1436032 significantly prolongs survival in a mouse model with transplanted human 
astrocytoma xenografts harboring the IDH1R132H mutation (Pusch et al., 2017). Since 2016 
this inhibitor is tested in clinical phase I/II trials.  
 
Another approach to affect mutant IDH1 is the induction of antitumor immunity through a 
peptide-based vaccine targeting IDH1R132H. It could be shown that IDH1R132H contains an 
immunogenic epitope that can be used for mutation-specific vaccination. Peptide vaccination 
of mice harboring human MHC class I and II presenting IDH1R132H peptide aminoacid 123-
142, evokes a mutation specific antitumour immune response. As this IDH mutation exists in 
all tumor cells of the glioma, this mutation-specific anti-IDH1R132H vaccine seems to be a 
viable therapeutic strategy to treat these tumors (Schumacher et al., 2014).   
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1.5 IDH1 and secondary alterations in gliomagenesis 
Mutations of IDH1 appear during early stages of gliomagenesis, which is followed by 
additional genetic alterations. The below explained alterations commonly describe different 
tumor entities, namely oligodendroglioma and astrocytoma, which are the focus of this 
project.  
 
TP53 
TP53, is the gene encoding protein 53 (p53) and is involved in many different types of cancer. 
The p53 protein is an important cell-cycle checkpoint regulator between G1/S and G2/M 
transition. If cell cycle arrest and DNA repair was not successful, it triggers the apoptotic cell 
death pathway (Brown and Wouters, 1999). In further consequence, a knock-out of TP53 
would lead to missing DNA repair, allowing DNA damage to occur unimpeded and to a 
decrease in apoptosis. This scenario is well known for human cancers. Additionally, enhanced 
proliferation and accumulation of further mutations takes place. Most of the mutations are 
missense mutations, inducing an impaired function of p53 and are located on several spots in 
exons 4-10. As known for the two-hit theory of tumor suppressor genes, the allele on 
chromosome 17p next to the mutant allele is also mutated. Examining expression of p53 with 
immunohistochemistry is often used in diagnostics (Otani et al., 2017; Takami et al., 2015). 
TP53 mutations are found in 25-30% of GBMs, >50% of astrocytomas and anaplastic 
astrocytomas (Ohgaki and Kleihues, 2011). 
 
ATRX 
Alpha-thalassemia/mental retardation syndrome X-linked (ATRX) is a gene located on the X 
chromosome q13 and encodes for the ATRX protein. ATRX plays an important role in 
chromatin remodeling and functions at the telomeres. Given the fact that ATRX is located on 
the X chromosome, a single inactivating mutation is sufficient for a complete loss of ATRX 
function. This loss of ATRX induces telomere destabilization, alternative lengthening of 
telomeres (ALT phenotype) and probably leads to genetic instability. Mutations of ATRX 
were detected in 33% of grade II and 46% of grade III gliomas, as well as in 80% of 
secondary and 7% of primary GBMs. This alteration overlaps with IDH1/2 and TP53 
mutations across tumors of different WHO grades (Liu et al., 2012). The mutation type of 
ATRX is either truncating mutations or missense mutations. Mutations can be detected with a 
negative staining in immunohistochemistry, serving as a surrogate marker in clinical practice 
(Liu et al., 2012; Reuss et al., 2015). 
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1p/19q Loss of heterozygosity (LOH) 
A 1p/19q loss of heterozygosity belongs to the molecular signature of oligodendroglioma and 
appears in all of the cases (Louis et al., 2016b). This particular location of the chromosomal 
arms originates due to an unbalanced translocation with a break point in the area of the 
centromeres. In a cohort of 764 gliomas, genome-wide characterization revealed that all 
tumors with a complete 1p/19q co-deletion are mutated on either IDH1 or IDH2 (Labussiere 
et al., 2010). Whole exome sequencing studies analyzed the genes that are affected by the 
translocation. It was found that inactivating mutations of the tumor suppressor genes FUBP1, 
located on chromosome 1p, and CIC, located on chromosome 19q, appear subsidiary to the 
co-deletion (Bettegowda et al., 2011; Sahm et al., 2012c). Mostly, gliomas harboring a 
1p/19q co-deletion present morphological features of oligodendroglioma and are associated 
with sensitivity to chemo- and radiation therapy in addition to a better prognosis (Cairncross 
et al., 2013).  
 
CIC 
The Drosophila Capicua (cic) HMG-box repressor is a key sensor of receptor tyrosine kinase 
(RTK) signaling in both Drosophila and mammals. Recent evidence suggests that CIC affects 
RTK-dependent responses, which are linked to cell proliferation and cancer (Tseng et al., 
2007). The repressive function of CIC to the downstream targets of the RAS/MAPK pathways 
points towards a role as a tumor suppressor gene in carcinogenesis. CIC is altered in the 
majority of oligodendrogliomas by somatic mutations and insertions/deletions (Bettegowda et 
al., 2011; Yip et al., 2012). About 70% of oligodendrogliomas harbor a CIC mutation 
whereas it is only very rarely found in astrocytomas (Sahm et al., 2012c; Yip et al., 2012). It 
is believed that CIC mutations in association with IDH1 mutations cooperatively regulate 
tumorigenesis (Jiao et al., 2012; Sahm et al., 2012c). In line with this, a cooperative increase 
of intracellular 2-HG level was reported. This led to a reduction of clonogenicity and slower 
proliferation in the cell lines. However, it remains unclear how this regulates or fosters 
tumorigenesis in vivo (Chittaranjan et al., 2014).  
 
pTERT 
Telomerase reverse transcriptase (TERT) is the catalytic site of the telomerase complex and 
upregulation of TERT increases telomerase activity. This ability is an essential criterion for 
cancer cells, as it allows indefinite extension of the telomeres and by this, immortalization. 
Mutations located in the promoter region of TERT (pTERT) were first described in melanoma 
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and were later discovered in glioma as well. pTERT mutations do occur almost always at one 
of two hot spots as C to T transitions and the frequency of mutations depends on the type of 
glioma. Mutations are often found in primary GBM and oligodendroglioma but rarely in 
diffuse and anaplastic astrocytoma. Both telomerase activity affecting mutations, ATRX and 
pTERT, occur mutually exclusive in glioma (Arita et al., 2013; Horn et al., 2013).  
 
1.5.1 Association of IDH mutations with TP53 and ATRX mutations in astrocytoma 
IDH1 mutations are believed to occur before TP53 or 1p/19q co-deletions and they are 
strongly associated with both alterations. A high percentage of grade II and III diffuse 
astrocytomas and secondary GBMs harbor mutations of the TP53 gene. The percentage for 
IDH mutated infiltrating astrocytomas with this secondary alteration is even higher. In diffuse 
astrocytomas (WHO grade II), 63% contain an alteration of TP53 and an IDH1 mutation 
(Watanabe et al., 2009). Furthermore, in a series of 939 tumors, 80% of anaplastic 
astrocytomas WHO grade III) harboring an IDH mutation also have a TP53 mutation.  
 
The combination of IDH1 and TP53 mutation is associated with inactivating mutations of 
ATRX. 363 brain tumors with different histology were analyzed for ATRX mutations. They 
occurred most frequently in grade II and III astrocytomas (67%) and secondary GBMs (57%). 
In contrast, the alterations did only occur in low percentages in primary GBMs (4%), 
oligodendroglial tumors (14%) and pediatric GBMs (20%). Except from one tumor, all 
infiltrating gliomas harboring an ATRX alteration additionally had an IDH1 mutation. Of 
those tumors, 94% exhibited an alteration in TP53. An ALT phenotype could be associated 
with 98% of the tumors with an ATRX mutation and a concomitant IDH1 mutation. Thus, 
IDH1 mutant astrocytomas show a common molecular signature with TP53 and ATRX 
mutations and are often associated with ALT (Figure 6) (Jiao et al., 2012). 
 
1.5.2 Association of IDH mutations with 1p/19q co-deletions in oligodendroglioma 
1p/19q co-deletions and IDH mutations are defining oligodendroglioma and are mutually 
exclusive with the molecular signature of astrocytoma, which is IDH, TP53 and ATRX 
mutations. Patients with oligodendroglial tumors bearing the 1p/19q co-deletion and pTERT 
mutations usually have a better prognosis compared to astrocytomas. In a study with 
heterogeneously treated patients, median overall survival was eight years (Jiao et al., 2012). 
In summary, the molecular signature describing oligodendroglioma consists of IDH as well as 
pTERT mutations and the co-deletion of the chromosomal arms 1p/19q (Figure 6).  
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Figure 6. Overview of the altered genes that define different subgroups of gliomas. The 
black box indicates the molecular alterations important for this project having major 
implications for the development of astrocytoma and oligodendroglioma. AA = anaplastic 
astrocytoma, GBM = glioblastoma, PXA = pleomorphic xanthoastrocytoma. Modified from 
(Appin and Brat, 2015). 
 
The knowledge on molecular alterations defining astrocytoma and oligodendroglioma was 
essential in defining the aims of the study as described below. 
 
1.6 Aims of the study 
The overall aim of this project was to develop a mouse glioma model based on neural stem 
cells (NSCs) that derive from conditional Idh1R132H knock-in mice. Regarding the different 
molecular landscapes of glioma subtypes, stem cells were prepared that harbor specific 
secondary mutations. Subsequently, the in vitro behavior of those cells was compared to the 
single mutants. Next, intracranial injections were performed with the murine neural stem cells 
into immunodeficient mice. Objectives of this project were as follows: 
1. NSCs will be established harboring the conditional knock-in Idh1R132H mutation and/or 
additional p53-/- mutations. Validation of the respective cell lines will be performed and 
effects of the mutations examined on functional level. 
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2. A conditional Cic knock-out mouse model will be established and NSCs produced from 
these mice. After validation, the knock-out of Cic will be investigated alone and in the 
presence of Idh1R132H on functional level. 
3. Next, intracranial injections will be performed with the established NSCs having the 
glioma lineage-defining mutations.  
4. The maximal observation duration of tumor growth monitored by regular MRI 
investigations will be one year post NSC injection. Afterwards, all tumor samples will be 
characterized on histological level and compared to the hallmarks of human glioma 
subtypes. 
5. Due to its close correlation in patients, the co-occurrence of Idh1R132H and epileptic 
seizures will be investigated with functional imaging. 
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2 Materials & Methods 
 
2.1 Matings of mice with different conditional alleles 
For the generation of NSCs, mice with different genotypes were crossed to yield littermates 
with the desired combination of conditional alleles. First, Idh1PM/flex (B6-
Idh1tm1(R132H)Avd/N) mice with a Bl6/N background, carrying the homozygous 
conditional Idh1R132H allele, were mated with mice harboring the heterozygous Rosa CreERT2 
transgene (B6;129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj). Consequently, littermates carried the 
heterozygous Idh1R132H mutation with the heterozygous Rosa CreERT2 transgene or were 
non-inducible controls. To yield the genetic alterations that were described in astrocytoma, 
the heterozygous Idh1PM/flex and Rosa CreERT mice were crossed with mice carrying the 
homozygous Tp53 floxed alleles (Trp53tm1Brd). Prior to NSC generation, matings were 
scheduled where mice carrying the heterozygous Idh1R132H allele, the heterozygous Rosa 
CreERT2 transgene and the homozygous Tp53 floxed allele were crossed with mice harboring 
the homozygous Tp53 floxed allele only. As a result, littermates always carried the 
homozygous Tp53 floxed alleles either with or without the Idh1R132H allele and were either 
inducible or not, serving as negative controls.  
 
2.2 Generation of Cic flox mice 
Attempts to mate homozygous Cic flox mice (JM8-Cictm1a(KOMP)Wtsi) resulted in small 
litters and genotyping has shown that no homozygous littermates were born at all. After 
searching for possible reasons, it was found that the original ES constructs were incorrectly 
annotated. Obviously, the flippase recognition target (FRT) cassette containing e.g. the 
resistance gene was still present in the cells and homozygous expression is lethal in mice. To 
get rid of the resistance cassette, homozygous Cic mice were crossed with flippase (Flp) mice, 
expressing the recombinase flippase, which mediated the recombination of the FRT sites. 
Prior to the next matings, littermates were genotyped to check for successful recombination 
and in a next step, mice were crossed in order to eliminate Flp again to finally yield the 
correct Cic construct. 
 
Subsequently, for the generation of neural stem cells with the common genetic alterations of 
oligodendroglioma, matings were started with mice carrying the heterozygous Idh1R132H 
allele, the heterozygous Rosa CreERT2 transgene and the homozygous Cic floxed alleles and 
mice carrying the homozygous Cic floxed alleles only. Also in these matings, littermates 
carried single as well as double mutants and the respective controls.  
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2.3 Chemicals 
If not otherwise mentioned, all standard chemical products were purchased from Sigma 
Aldrich. 
 
2.4 Genotyping 
Tail DNA isolation was performed with the SampINTM Direct PCR Kit (highQu, DPK0105) 
according to manufacturer’s protocol. After adding 50 µl of the lysis buffer and protease 
buffer mastermix, tails were first lysed for 5 min at 75 °C. Subsequently, tubes were 
vigorously vortexed once and further incubated for 10 min at 95 °C. Addition of 450 µl PCR 
H2O and a 1 min centrifugation step at max rpm (Eppendorf, 5415R) was carried out before 
supernatant could be applied for genotyping PCRs. Exact concentration of extracted DNA 
was measured with NanoDrop (PeqLab) and approximately 100 ng were applied for PCR. If 
genotyping of cell lines was performed, DNA was extracted with the NucleoSpin Tissue Kit 
(Macherey-Nagel), according the manufacturer’s protocol. PCRs were conducted with the 
Allin TM HS Red Taq polymerase, which is also part of the highQu kit. The PCR approach 
was adjusted dependent on the gene of interest and the combination of primers needed (Table 
1), as well as the annealing temperature (AT) and the elongation time (ET) of the PCR 
program (Table 2). Thermocycling was carried out with a T-personal 48 PCR machine 
(Biometra).  
 
Table 1. PCR approach for genotyping. Calculation was adjusted according to the 
combination of primers. 
2x Allin TM HS Red Taq 10 µl 
Primer I-IV each 1 µl 
DNA 1 µl 
H2O 
ad  
20 µl 
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Table 2. Thermocycling conditions for genotyping. Annealing temperature and elongation 
time were adapted according to the respective primers. Black arrow indicated number of 
cycles. 
 
 
Subsequently to PCR, the whole sample (20 µl) was loaded onto a 2% agarose gel (AXYGEN 
Bioscience) with ethidiumbromide (Roth). Low range DNA ladder was used (Fast Ruler, 
Thermo Scientific) as size marker. 
 
Table 3. Overview of all genotyping PCRs and specificities. Respective primers are listed 
in supplement table 2. 
Genotype Primer AT (°C) 
ET 
(s) Cycles 
Gel 
(min) 
Wild-type 
(bp) Mutant (bp) 
Idh1R132H P259/262 58 9 35x 90 529 600 (targeted allele) 
p53 flox P307/308 66 5 35x 65 270 350 (targeted allele) 
Rosa P268/269
/270 
55 5 35x 40 603 
(P268/269) 
800 (P268/270, P270 
is located in Cre) 
Cic P636/638 58 9 35x 60 551 769 (targeted allele) 
Flp I P643/644 58 9 35x 60 - 725 (P643/644 both 
bind to Flp) 
Flp II P645/646 58 9 35x 60 324 - 
FRT 
control I 
P636/637 56 5 35x 60 - 383 (only if NeoR is 
removed) 
FRT 
control II 
P636/404 58 9 35x 60 - 401 (only if NeoR is 
removed and 
recombination 
ensued) 
 
2.5 Preparation of neural stem cells 
Newborn mice were sacrificed on day P1 with decapitation. In the following, heads were 
collected in falcon tubes with 5 ml ice-cold phosphate buffered saline, PBS (Gibco) and the 
respective tails were kept in tubes for genotyping purposes. Under sterile conditions, the 
whole brain was removed, the cerebellum was discarded and the cerebrum was chopped into 
fine pieces with a scalpel. For subsequent enzymatic dissociation, material was collected in a 
falcon tube containing 5 ml sterile filtered Papain Dispase DNase (PDD) solution. Enzymatic 
dissociation was performed for 30 min at room temperature on a rolling incubator. 
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Table 4. Recipe for preparation of the PDD solution. After solving of the supplements, 
solution was sterile filtered and stored at -20 °C. 
Supplement Concentration / Volume added Company 
Hank’s balanced salt solution 
(HBSS), without Mg2+ and Ca2+ 100 ml Gibco 
MgSO4 12.4 mM / 149 mg AppliChem 
Papain 0.01% / 370 µl Sigma-Aldrich P-3125 
Dispase 2 0.1% / 100 mg Roche 165859 
DNase 0.01% / 1 ml Roche 1284932 
 
After incubation, suspension was centrifuged for 5 min at 800 rpm. Supernatant was removed 
and the remaining pellet was washed and resuspended in 1 ml PBS. This was performed 
twice. Thereafter 1 ml of Neurobasal medium (Gibco) with supplements was added to the 
pellet and it was dissociated by pipetting up and down with a 1 ml tip. Finally, dissociated 
cells were transferred into T25 ultra-low attachment flasks (Corning, 3815), containing 5 ml 
Neurobasal medium (Table 5). Cells were kept under standard cell culture conditions 
(Neurobasal medium, 37 °C, 5% CO2).  
 
Table 5. Recipe for Neurobasal medium for NSC cultivation. The listed supplements were 
added to 500 ml of Neurobasal medium. 
Supplement Concentration Company 
B27 Supplement 5% Gibco 
GlutaMAX 1% Gibco 
Murine EGF 20 ng/ml Peprotech, 315-09 
Murine basic-FGF 20 ng/ml Peprotech, 450-33 
Penicillin/Streptomycin 1% Gibco 
 
2.6 Passaging and induction of genetic alterations 
All newly prepared NSCs were cultured under standard cell culture conditions as described 
above. After preparation, cells were incubated until neurospheres were clearly visible. For 
passaging, cell suspension was transferred into a falcon tube and neurospheres were allowed 
to descend until a pellet was visible. The supernatant, containing single cells and dead cells, 
was discarded leaving behind 1 ml. Using a 1 ml pipette, neurospheres were mechanically 
dissociated by pipetting up and down. For standard passaging, the 1 ml single cell suspension 
was filled back into the culture flask, containing about 5 ml fresh Neurobasal medium. 
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For the induction of the genetic alterations via the Cre recombinase system, 1 µM  
4-Hydroxytamoxifen (4-OHT, Sigma-Aldrich) was directly added to the cell culture medium 
after passaging of the cells. To make sure that the time of treatment was sufficient, 4-OHT 
remained in the culture medium for one week. An exception for this was the induction of the 
knock-out of Cic. Given the fact that the genomic region that has to be recombined is fairly 
large, treatment with 4-OHT was carried out twice. This strategy led to successful induction 
of the knock-out. Before the start of the experiments, all induced cell lines were checked for 
induction with Western blot, PCR as well as immunohistochemistry. 
 
For preparation of the cells for the respective assays, cells were counted with a Spector 2.0 
Handheld Automated Cell Counter (Merck Millipore).  
 
2.7 Proliferation assay 
The CellTiter-Glo 3D Cell Viability Assay (Promega, G9683) was used to analyze the 
proliferative capacity of the cells. This assay is designed to analyze cell viability in spheroids 
growing in 3D cultures. The reagent of this assay permeates large spheroids. The CellTiter-
Glo 3D reagent allows the luminescent measurement of the ATP levels, which serve as an 
indicator for cell viability. ATP is released by cell lysis and is used by Luciferase to generate 
a luminescent signal that correlates with the number of viable cells in the respective culture or 
microtissue. The CellTiter-Glo 3D Cell Viability Assay was performed in 96-well plate 
(Corning, 353296) format with 5000 cells per well, containing 100 µl of medium in total 
(unless otherwise described). Cells were seeded in eight replicas and induced cell lines were 
always compared to non-inducible controls. Cell viability measurements were carried out 
after indicated incubation times, which was mainly on day 0, 3 and 5. On the respective day 
of the experiment, 100 µl of the CellTiter-Glo 3D reagent was pipetted into each well and the 
96-well plate was mixed while shaking at room temperature for 6 min. In the following, the 
luminescent signal was detected with a FLUOstar Omega plate reader (BMG Labtech).  
 
2.8 SDS-Page and Western blot 
For Western blot experiments, unless otherwise described, 300 µl cell suspension from 
induced cells and their respective controls were transferred into Eppendorf tubes. After 
centrifugation at 1000 rpm for 3 min, cell pellet was washed with 500 µl PBS and 
centrifugation was repeated at 3000 rpm. Next, supernatant was discarded and pellets were 
resuspended in 60 µl NP40 lysis buffer (150 mM NaCl, 50 mM Tris-HCl, 0.1% Nonidet-P40 
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(biomol), pH 8.0) + protease inhibitor cOmplete mini, EDTA-free (Roche)). Lysis was carried 
out by three freeze-and-thaw cycles. Centrifugation at 11000 rpm for 10 min was used to 
remove the residual debris. The supernatant containing the isolated proteins was collected in a 
new tube. For exact measurement of the protein concentration, a bicinchoninic acid (BCA) 
assay was performed. This assay was carried out using the Piece Protein Assay Reagent 
(Thermo Scientific) according to manufacturer’s protocol. The fluorescent signal was 
detected after 30 min incubation at 37 °C with a FLUOstar Omega plate reader (BMG 
Labtech). Samples were prepared in PCR tubes (Biozym), containing 5 µl of 4x LDS sample 
buffer (NuPAGE Novex system, Thermo Scientific), 2 µl of 10x Sample reducing agent 
(NuPAGE Novex system, Thermo Scientific), 30 µg protein and water ad 20 µl. Samples 
were quickly spun down and incubated at 96 °C for 5 min. Afterwards, tubes were quickly put 
on ice before the whole sample was loaded on ready-to-use 4-10% Bis-Tris protein gels 
(Invitrogen). SDS-PAGE chamber (X Cell Sure Lock, Invitrogen) was filled with MOPS 
buffer (NuPAGE Novex system, Thermo Scientific) and gel was running for 60 min at 200 V. 
However, if proteins of interest were smaller than 20 kDa, MES (NuPAGE Novex system, 
Thermo Scientific) instead of MOPS buffer was used. Afterwards, the gel was transferred 
onto a 0.45 µm nitrocellulose membrane (for proteins smaller than 20 kDa, 0.22 µm, 
Invitrogen), with a semidry-blotting device (FastBlot B44, Biometra) for 60 min and 100 mA 
per gel. To check for the transmission of the protein, a Ponceau S (AppliChem) staining was 
performed for 2 min, before membrane was blocked. Blocking was performed with 5% milk 
powder (AppliChem) dissolved in Tris-buffered saline-Tween, TBS-T (TBS, AppliChem; 
0.05% Tween, Fisher Scientific) at room temperature for 60 min while shaking. This step was 
followed by overnight incubation with primary antibodies at 4 °C (Table 7). Primary as well 
as secondary antibodies were diluted in 5% milk/TBS-T. After overnight incubation, 
secondary antibodies were incubated for 60 min at room temperature. Washing in between the 
different steps was always done three consecutive times for 10 min with TBS-T. If proteins of 
interest were very large (>140 kDa), protein was loaded onto 3-8 % Tris-Acetate gels 
(Invitrogen) and Tris-Acetate buffer (NuPAGE Novex system, Thermo Scientific) was used 
during gel electrophoresis. Subsequently, wet-blotting was performed instead of semidry 
blotting. To do so, protein gel and a 0.45 µm nitrocellulose membrane was embedded into a 
wet blot chamber (X Cell II Blot Module, Invitrogen) in between eight sponges and filled 
with transfer buffer (Table 6). After blotting for 60 min at 220 mA, the protocol was further 
carried out the same way as described above for smaller proteins. 
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Table 6. Recipe for preparation of transfer buffer. For Western blot analysis of proteins 
smaller than 140 kDa, 5 ml 10% SDS was also added. 
Supplement Volume added Company 
20x Transfer buffer 50 ml NuPAGE Novex system, 
Thermo Scientific 
Methanol 100 ml Sigma-Aldrich 
Antioxidant 1 ml NuPAGE Novex system, 
Thermo Scientific 
 Ad 1 l  
 
Table 7. Primary antibodies used for Western blot experiments. Antibodies were diluted 
in 5% milk/TBS-T and incubated at 4 °C overnight while rolling. 
Antibody 2
nd 
Antibody 
Dilution 
for WB Clonality Size (kDa) Company 
b-Actin rabbit 1:1000 monoclonal 42 Cell Signaling 
IDH1R132H mouse 1:300 monoclonal 47 Dianova 
p53 mouse 1:300 monoclonal 53 Cell Signaling 
CIC rabbit 1:1000 polyclonal 164 Abcam 
Cleaved Caspase 3 rabbit 1:300 polyclonal 17, 19 Cell Signaling 
Cleaved Caspase 7 rabbit 1:300 polyclonal 20 Cell Signaling 
Cleaved PARP rabbit 1:300 polyclonal 89, 116 Cell Signaling 
P-Histone H2AX rabbit 1:500 monoclonal 15 Cell Signaling 
H2A mouse 1:500 monoclonal 14 Cell Signaling 
 
Table 8. Secondary antibodies used for Western blot experiments. Antibodies were 
diluted in 5% milk/TBS-T and incubated at room temperature for 60 min while rolling. By 
use of fluorescent antibodies, incubation was carried out in the dark. 
Antibody Species reactivity 
Dilution for 
WB Company 
Goat anti-mouse IRDye 680RD, 700 nm mouse 1:10000 LI-COR Biosciences 
Goat anti-rabbit IRDye 680RD, 700 nm rabbit 1:10000 LI-COR Biosciences 
Goat anti-mouse IRDye 800CW, 800 
nm 
mouse 1:10000 LI-COR Biosciences 
Goat anti-rabbit IRDye 800CW, 800 nm rabbit 1:10000 LI-COR Biosciences 
Anti-rabbit IgG HRP-linked Antibody rabbit 1:4000 Cell Signaling 
Anti-mouse IgG HRP-linked Antibody mouse 1:4000 Cell Signaling 
 
Western blot analysis was performed after incubation with either HRP-linked antibodies or 
fluorescent antibodies with a LI-COR Odyssey Fc imaging system (LI-COR Biotechnology). 
Prior to development of the blot, HRP substrate LumiGLO Reserve chemiluminescent 
substrate (KPL) was added to the membrane, incubating for 2 min, when HRP-linked 
antibodies were used. Afterwards, exposure time of the imaging system was 10 min for these 
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antibodies and 2 min for fluorescent antibodies respectively. The used secondary antibodies 
are listed in table 8. 
  
2.9 Reverse transcription PCR 
Reverse transcription PCRs were performed to analyze the knock-out of Cic on RNA level. 
Before cDNA was synthetized, RNA was extracted from 300 µl cell suspension following the 
manufacturers protocol, with the NucleoSpin RNA Kit (Macherey-Nagel). RNA 
concentration of the samples was measured with Nano Drop and 1 µg was used for 
subsequent cDNA synthesis. Protocol for cDNA synthesis was carried out following 
manufacturers protocol belonging to the Revert Aid H Minus First Strand cDNA Synthesis 
Kit (Fermentas), with some adjustments. In a first step, 1 µg RNA was added to 0.2 µg 
random hexamer primer and nuclease-free water ad 11.5 µl. After incubation for 5 min at 65 
°C, samples were placed on ice. The following steps were carried out as per protocol, adapted 
to random hexamer primers. Subsequently, PCR for detection of Cic was carried out with 
GoTaq G2 DNA polymerase (Promega) as listed in table 9. 
 
Table 9. Reaction setup for GoTaq G2 polymerase-mediated PCR amplification. 
Component 25 µl reaction 
GoTaq DNA polymerase 12.5 µl  
10 µM forward primer (P714 or 716) 1.25 µl 
10 µM reversed primer (P715 or 717) 1.25 µl 
template cDNA 1 µl 
nuclease-free water 9 µl 
 
The reaction components were gently mixed and quickly spun down before tubes were 
transferred to a PCR machine. Thermocycling was adapted due to annealing curves analysis 
and elongation times suitable for the primers chosen, before the final protocol was carried out 
as listed in table 10. 
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Table 10. Thermocycling conditions for GoTaq polymerase-mediated PCR 
amplification. * was adapted due to the Cic primers chosen. Black arrow indicates number of 
cycles. 
 
 
 
 
 
 
 
2.10 Soft agar assay 
The CellTiter-Blue Cell Viability Assay (Promega, G9683) was used to measure the colony 
formation rate in an anchorage-independent manner. This assay is a single treatment assay, 
measuring cell viability using a redox indicator dye resazurin, which allows examining colony 
formation rate using fluorescence. Viable cells are able to carry out the reduction of resazurin 
to the fluorescent product resorufin, which dead cells do not, due to membrane damage. After 
this reaction has taken place, resorufin leads to a strong increase in fluorescence, which is 
directly proportional to the number of viable cells. Fluorescence measurements after 
conversion to resorufin were carried out at the excitation and emission peaks 579 nm and 584 
nm respectively. Before cells could be seeded, the following 2x and 4x media were prepared 
in 50 ml Neurobasal medium (for information about the respective supplements, see table 5). 
 
Table 11. Preparation of 2x and 4x medium for soft agar layers. The respective 
supplements were diluted in 50 ml Neurobasal medium in total.  
Supplement 2x Medium 4x Medium 
B27 Supplement 2 ml 4 ml 
GlutaMAX 1 ml 2 ml 
Murine EGF 20 µl 40 µl 
Murine bFGF 20 µl 40 µl 
Penicillin/Streptomycin 1 ml 2 ml 
 
In addition, 4x agar was prepared and for this purpose, 2.8 g low-gelling agarose (Sigma-
Aldrich) was slowly diluted during boiling up in a microwave and stirring in between. Before 
cells could be seeded, the freshly prepared 4x agar was diluted 1:1 with 2x medium (both at 
44 °C) and 50 µl was pipetted into each well of the 96-well plate (Greiner, 655976). Plates 
were left at 4 °C overnight before preparation of the cell dilutions. For preparation of the next 
agar layer, bottom layer agar was prepared at 44 °C as explained above and cell suspensions, 
98 °C 30 s 
98 °C 5 s 
52 °C* 10 s 
72 °C 30 s* 
72 °C 2 min 
10 °C ¥ 
30x 
Materials & Methods 
 
	 35	
finally containing 2000 cells/well, were prepared in 37 °C pre-warmed 2x medium. 
Immediately before seeding, cell suspension was mixed with bottom layer agar 1:1 and gently 
mixed with a pipette. In the following, cells were seeded in eight replicas and induced cell 
lines were always compared to non-inducible controls. Wells in which air bubbles were 
clearly visible, or in which any of the agar layers was accidentally touched with a pipette tip, 
were excluded from experiments. After seeding, plates were allowed to cool down for 30 min 
at room temperature before 50 µl of 4x medium was added per well. Subsequently, plates 
were incubated for 24 h at 37 °C before a final layer containing 50 µl normal Neurobasal 
medium was also added (Figure 7). 
 
Cell viability measurements were carried out after seven days of incubation at 37 °C. On the 
respective day of the experiment, 40 µl of the CellTiter Blue reagent was added to each well 
and the 96-well plate was further incubated at 37 °C for eight hours. In the following, the 
fluorescent signal was detected with a FLUOstar Omega plate reader (BMG Labtech). 
 
Figure 7. Schematic representation of the soft agar assay. Details and quantities are given 
per well. RT = room temperature.  
 
2.11 2-HG assay 
The concentration of 2-HG present in either supernatant or cell lysates was measured by an 
enzymatic quantification assay, which was developed in the Department of Neuropathology at 
Heidelberg University (Balss et al., 2012).  
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Figure 8. Schematic of the 2-HG quantification assay. a) 2-Hydroxyglutarat dehydrogenase 
(HGDH) catalyzes the conversion of 2-HG to a-KG and the reduction of NAD+ to NADH. b) 
The level of NADH is detected by the conversion of resazurin to resorufin, catalyzed by 
diaphorase. Resorufin as a fluorescent product is excited at 540 nm and subsequently detected 
at 610 nm (Balss et al., 2012).  
 
The enzyme HGDH catalyzes the oxidation of 2-HG to a-KG and the simultaneous reduction 
of NAD+ to NADH (Figure 8). NADH is used by the enzyme diaphorase to convert resazurin 
to the fluorescent resofurin. By this the amount of 2-HG in the probe linearly correlates with 
the resofurin signal measured. 
 
To quantify 2-HG in the supernatant, 500,000 cells were seeded per well in 6-well ultra-low 
attachment culture plates (Corning) and grown for four days before harvesting. The content of 
each well was transferred into Eppendorf tubes and centrifuged for 5 min at 1000 rpm. To 
detect intracellular 2-HG levels, cell pellets were washed with PBS and subsequently lysed in 
125 µl of NP40 buffer, as described in chapter 2.8. Before the measurement, 25 µl perchloric 
acid (PCA) was added to 100 µl of the sample and 5 min incubated on ice to precipitate 
proteins and metabolites that would otherwise disturb the assay. Next, the samples were 
centrifuged at 14,000 rpm for 7 min. Subsequently, 100 µl of the supernatant were transferred 
to new tubes, already containing 5 µl of neutralization solution (BioVision, Deproteinizing 
Sample Preparation Kit, K808-200). Incubation on ice and centrifugation was repeated once 
and supernatants were transferred to new tubes. A serial dilution from 0 to 500 µM 2-HG 
diluted in standard Neurobasal medium served as a standard. The assay was carried out in 96-
well plates (BRANDplates, 781608) and technical triplicates. 75 µl of the prepared master 
mix was used per well. The master mix contained 100 mM HEPES pH 8 (AppliChem), 100 
µM NAD+ (AppliChem), 0.01 µg/µl HGDH (produced by Jessica Eisel, as described in (Balss 
et al., 2012)), 0.01 U/ml diaphorase (MP Biomedical) and 125 µM resazurin (AppliChem), 
diluted in H2O. 25 µl of the respective samples was added per well. The reaction was 
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incubated in the dark for 15 - 60 min at room temperature. Afterwards, fluorescence was 
measured with the FLUOstar Omega reader at 540 nm and 610 nm excitation and emission 
respectively. 
 
2.12 Dotblot 
The dotblot method was chosen to investigate whether the different alterations induce 
differences in DNA methylation. For this purpose, DNA was blotted onto a membrane and 
levels of 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) were analyzed with 
the respective antibodies. DNA concentrations for dotblot experiments were measured 
precisely with the QUBIT dsDNA BR assay (Thermo Scientific) after 10 min of sonification. 
This assay was applied, because it detects DNA and not RNA by specific intercalation into 
double-stranded DNA. Analysis was performed in duplicates and a standard row of 0, 1, 5, 10 
and 20 ng/µl control DNA was used. Samples were measured with the FLUOstar Omega plate 
reader at 485 nm and 530 nm. For further sample preparation, DNA was denatured (2mM 
NaOH, 50 mM EDTA) for 10 min at 95 °C and afterwards neutralized (2M 
Ammoniumsulfate, pH 7) for 10 min on ice. Serial dilutions in TE-buffer were prepared on 
ice from 1000 ng to 31.25 ng. Subsequently, 50 µl of all samples in duplicates were loaded 
onto a nylon membrane (GE Healthcare, positive charged transfer membrane, RPN 203B), 
which already had been fixed in the dotblot apparatus (BioRad). After application of vacuum 
inducing the blotting process, membranes were washed, baked at 80 °C for 2 h (Jouan) and air 
dried overnight. Before incubation with antibodies, membrane loading was assessed with 
methylene blue. Blocking of the membrane was done as explained in section 2.8. Incubation 
with primary (Table 12) as well as secondary antibodies (Table 8) were both done for 1 h. The 
antibodies were diluted in 5% milk/TBS-T. Blots were developed with HRP substrate at the 
LI-COR imaging system as explained in paragraph 2.8.  
 
Table 12. Primary antibodies used for dotblot experiments. Respective antibodies were 
diluted in 5% milk/TBS-T. 
Antibody Concentration Company 
Hydroxymethylcytosine (5hmC) 1:1000 Active Motif #39791 
Methylcytosine (5mC) 1:1000 Active Motif #39649 
 
2.13 Histology of neurospheres 
For histology, neurospheres were spun down for 5 min at 500 rpm. The supernatant was 
removed and the pellet was carefully resuspended in 4% buffered formalin (54 mM NaH2PO4, 
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28 mM Na2HPO4) and fixed overnight at 4 °C. On the next day, the fixed spheres were 
pipetted in recesses of a 1.5% low-gelling agarose (Sigma-Aldrich) block that was produced 
with a hand-crafted form. The embedding in paraffin as well as the preparation of the slices 
and the respective control haematoxylin & eosin (HE) stainings were performed by 
technicians of the Clinical Cooperation Unit Neuropathology, Heidelberg. Subsequent 
immunohistochemistry was performed manually as described in 2.14.  
 
2.14 Immunohistochemistry 
1 µm slices were cut from paraffin embedded (FFPE) blocks with a Microm HM 355 S 
microtome (Thermo Fisher). Slices were dried at 80 °C for 15 min and stained manually with 
the respective antibodies. Slices were rehydrated by washing twice in xylene, following 
washing twice in 100% ethanol, once 90% ethanol, once 70% ethanol and finally in water, 
each for 2 min. Then slices were pretreated with Cell Conditioner 1 (pH 8; Ventana Medical 
Systems, 950-124) for 30 min at 100 °C. Subsequently, slices were incubated in 3% H2O2 
(ChemSolute) diluted in TBS for 15 min at room temperature, following blocking with 5% 
FCS/TBS for 60 min. Primary antibodies (Table 13) were diluted in 5% FCS/TBS and 
incubated at 4 °C overnight. Slices were then incubated for 60 min with an immune 
peroxidase polymer anti-rabbit (Histofine Simple Stain MAX PO, Nichirei, 414141F). 
Afterwards, development of the stainings was performed with an 1:50 dilution of DAB for 
standard signal amplification (DAB-2V, Nichirei, 4253121F). Each slice was developed 
separately and staining was monitored with a standard microscope to yield the optimal signal. 
Counterstaining for detection of the cell nuclei and re-paraffinization with increasing 
concentrations of ethanol and xylene was performed in the routine laboratory of the Clinical 
Cooperation Unit Neuropathology. In case of mouse primary antibodies, the Histofine 
Mousestain Kit (Histofine, Nichirei, 414322F) was used in addition to the general staining 
protocol, following the manufacturers’ protocol. 
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Table 13. List of the primary antibodies used for immunohistochemistry experiments. 
Dilutions and pretreatment were established on mouse brain slices. 
Antibody 2
nd 
Antibody 
Dilution 
for IHC Pretreatment Clonality Company 
IDH1R132H mouse 1:50 C1 monoclonal Dianova 
p53 mouse 1:100 C1 monoclonal Cell Signaling 
CIC rabbit 1:50 C1 polyclonal Sigma-Aldrich 
Cre-
recombinase 
rabbit 1:250 C1 polyclonal Sigma-Aldrich 
Foxn1 rabbit 1:100 C1 polyclonal Antibody-online 
SOX2 rabbit 1:1000 C1 polyclonal Abcam 
Ki-67 rabbit 1:500 C1 polyclonal Abcam 
pHH3 mouse 1:500 C1 polyclonal Cell Signaling 
 
2.15 Intracranial injections of neural stem cells 
The in vivo study for the allograft model was approved by the governmental authorities 
(Regierungspräsidium Karlsruhe, Germany). Additional supervision was done by institutional 
animal protection officials in accordance with the US National Institutes of Health guidelines 
Guide for the Care and Use of Laboratory Animals (License number G-38/15 and G-155/12). 
Genetically altered NSCs and their respective controls were stereotactically implanted into the 
brains of 64 7-9-week-old female BALB/c nude mice (CAnN.Cg-Foxn1nu/Crl; Charles River 
Laboratories, USA). For PET experiments, six BALB/c nude mice with the same age were 
implanted with NCH551b cells and two with NCH644 cells. NCH551b is a primary patient-
derived secondary glioblastoma cell line that has an endogenous IDH1R132H mutation. 
NCH644 derives from a human primary glioblastoma, but lacks the IDH1R132H mutation. Both 
human cell lines were cultivated by and obtained from Dr. Stefan Pusch. 
 
Prior to surgeries, cells were mechanically dissociated and counted as described in 2.6. 
Subsequently, the needed amount of cells was spun down for 5 min at 300 rpm or if a pellet 
was not clearly visible, at 800 rpm. The supernatant was very carefully removed. The cell 
pellet was carefully resuspended in PBS to obtain a cell suspension with 100,000 cells/µl. 
Thereafter, cells were kept on ice until transplantation. 
 
Before surgery, mice were anaesthetized with an intraperitoneally injected Ketamin/Xylazin 
narcosis according to table 14, in a volume of 90 µl/10 g bodyweight. After injection, a 
remarkable number of mice died due to respiratory problems. To avoid these problems, later 
surgeries were performed with Isofluran (Baxter), starting with 3% at the beginning of 
narcosis, which was decreased to 2.5 % during the intracranial injection. 
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Table 14. Composition of injection anesthesia. Narcosis was freshly prepared every day and 
supplements were carefully measured with a syringe. 
Substitution Concentration Added volume Company 
Ketamin (Ketavet) 100 mg/ml 1.5 ml Pfizer 
Xylazin (Rompun) 20 mg/ml 0.5 ml Bayer 
NaCl  8 ml  
 
After a small cut with a scalpel (No. 21, Feather), the skin of the head was carefully put aside 
to view the location of the bregma. The intracranial injection was carried out 2 mm right of 
the sagittal suture, 3 mm rostral of the occipital suture and 3.5 mm deep. The exact location of 
implantation in the frontal cortex is depicted in figure 9. 
 
 
Figure 9. Scheme of the area of implantation. A NSCs were intracranially injected into the 
right frontal cortex, 2 mm right of the sagittal suture and 3 mm rostral of the occipital suture. 
B Depth of implantation above the ventricle indicated from coronal perspective (picture B 
was modified from the mouse brain atlas, C57BL/6J section 8). C Picture of a mouse during 
intracranial injection. 
 
Prepared cell solutions in PBS were implanted at a concentration of 100,000 cells/µl with a 
stereotactic device (51600, Stoelting) and injector device (Quintessential Stereotaxic Injector, 
53311, Stoelting) for exact application of the cells. Before cells were injected at a flow rate of 
1 µl/min, the injection needle (Hamilton, Syr 10 µl, 701N) was pulled back 0.5 mm. After 
injection of 200,000 cells, cells were allowed to settle for two more min before the syringe 
was removed. Cell suspension for application was renewed after every second implantation to 
avoid that cells coagulate. After removing the syringe, wounds were sewed with two surgical 
knots (Ethilon, Polyamide 6, black, 45 cm) and a dose of 100 µl Carprofen/PBS (50 mg/ml, 
Zoetis) was subcutaneously injected in the neck. 
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The health condition of each mouse was monitored daily for abortion criteria, which are loss 
of 20% body weight, ataxia, apathy or paralysis. Mice showing any of these symptoms were 
euthanized directly.  
 
2.16 Imaging and analysis 
During the experiment, mice were monitored with 1.5 T MRI scans to analyze possible space-
consuming lesions or tumor formation before the occurrence of any other symptoms. MRI 
scans were performed in cooperation with Dr. Manfred Jugold and Dr. Viktoria Eichwald at 
the imaging department for animals at the DKFZ Heidelberg. Measuring was performed 
according to the Bruker-RARE-sequence with the parameters listed in table 15. T1 
measurements were only performed in case of a detected lesion during T2 scans. If T1 
weighted recordings were performed, 70 µl of 0.5 mmol contrast enhancing agent (magnevist, 
Bayer) was injected per mouse 10 min prior imaging. 
 
Table 15. Imaging parameters set for T2 and T1 weighted scans during 1.5 T 
examinations.  
 T2 weighted image T1 weighted image 
Method Bruker-RARE Bruker-RARE 
No. of slices 20 20 
Image size 128 128 
Scan-time 2.17 min 2.4 min 
Slice thickness 1 mm 1 mm 
Echotime (TE) 85 ms 12 ms 
Pulse-repeating 
time (TR) 
4301.8 ms 647.392 ms 
 
PET-CT imaging 
Imaging was performed using an Inveon™ dedicated PET linked to a multimodality CT 
(Siemens Medical Solutions). For PET analysis, 4 h prior to tracer injection mice were fasted 
with free access to drinking water. Before imaging, mice were anaesthetized with 3.5% 
sevoflurane in air and 6-8 MBq of [18F] FDG were injected via the lateral tail vein in a total 
volume of 100 µl. During uptake of the radiotracer, mice were kept anaesthetized and kept 
warm with a heating pad. After an uptake time of 45 min, ten-minute static PET scans were 
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acquired. Afterwards, reconstruction was performed using filtered back projection (FBP) and 
OSEM2D. 
 
In addition to PET scans, anatomical CT scans were used for fusion imaging. The exposure 
time was 300 ms and scanning parameters were an X-ray voltage of 50 kV with an anode 
current of 500 µA. 180 rotation steps were done with a total rotation of 360°. The binning 
factor was 2 and the field of view was adjusted to 90.56 mm × 53.09 mm. For the 
reconstruction of images, a downsample factor of 2 was set. Afterwards, analysis of the 
reconstructed images was performed with the vendor software package Inveon™ Research 
Workplace (IRW) 2.2. 
 
9.4 T MRI 
During the last week of the mouse study, mice were also screened with a 9.4 T MRI to get a 
more precise image with a better spatial resolution. These experiments were carried out with 
the help of Dr. Ulf Neuberger and Manuel Fischer at the University of Heidelberg. 
Measurements were performed with a Biospec 94/20 9.4 T MRI and analysis was performed 
with the Paravision 6.0.1. software. If T1 weighted images had to be acquired, 0.5 mmol/ml 
contrast enhancing agent (Dotarem) was injected 10 min prior to imaging (Table 16).  
 
Table 16. Scanning settings for T2 and T1 weighted images during 9.4 T examinations.  
 T2 weighted image T1 weighted image 
Method TuroboRARE RARE 
No. of slices 15 15 
Image size 256 x 256 200 x 200 
Scan-time 2.40 min 5.0 min 
Slice thickness 0.7 mm 0.5 mm 
Echotime (TE) 33 ms 6 ms 
Pulse-repeating 
time (TR) 
2500 ms 1000 ms 
 
Brain preparation 
The brains of the euthanized mice were carefully extracted and fixated at 4 °C overnight in 
4% buffered formalin solution (54 mM NaH2PO4, 28 mM Na2HPO4). Before slice 
preparation, fixated brains were embedded in paraffin with a HistoStar Embedding 
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Workstation (Thermo Fisher). As shown in figure 10, the caudal parts of the brains were 
cryopreserved immediately after preparation by placing the specimens in liquid nitrogen and 
immediate storage at -80 °C. 
 
Figure 10. Schematic of the preparation of mice brains. The brain was cut in sagittal 
position through the area of implantation, which was still observable as a small dot in most of 
the cases. Rostral parts were fixed in formalin for preparation of paraffin slices, whereas 
caudal parts were cryoconserved for 2-HG measurements.  
 
Statistics 
All statistics was performed with Graph Pad Prism 7. Unless otherwise described, statistical 
significance was analyzed with two-sided unpaired t-tests of mean values and a p-value <0.05 
was assessed as significant. Details are given in the legend of the respective figures. 
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3 Results 
 
3.1 Generation of Cic flox mice 
Targeted Agouti ES-cells were obtained from Prof. Günther Schutz, DKFZ Heidelberg and 
implanted into Bl6/N blastocysts, which was performed by the transgenic mice core facility of 
the DKFZ. The resulting chimeras were checked for successful germline transmission. 
Attempts to generate homozygous Cic flox mice resulted in small litters and genotyping 
showed that no homozygous littermates were born at all. It was found that the original ES 
constructs were incorrectly annotated. The flippase recognition (FRT) cassette containing the 
Neomycin resistance gene was still present in the cells and homozygous expression is lethal in 
mice. To get rid of the resistance cassette, heterozygous Cic mice were crossed with flippase 
(Flp) mice. Prior to the next mating, littermates were genotyped to check for successful 
recombination and in a next step, mice were crossed with Bl6/N in order to eliminate Flp 
again to finally yield the correct Cic construct. 
 
3.2 Generation of neural stem cells with different genetic alterations 
Being able to investigate the role of the Idh1R132H mutation during the process of 
gliomagenesis and its effect in combination with other genetic alterations in vitro and in vivo, 
neural stem cells (NSCs) were prepared. These cells derive from conditional knock-in 
Idh1R132H mutated mice that are inducible via the Cre-recombinase system. Several 
combinations of stem cells were prepared, which includes different genotypes and the 
respective controls. The Cre-recombinase system was chosen in order to prevent embryonic 
lethality of Idh1R132H mice (Sasaki et al., 2012). For cells harboring an additional 
astrocytoma-lineage defining mutation, NSCs were prepared carrying the conditional 
Idh1R132H mutation, the Rosa CreERT2 transgene and a conditional Tp53 knock-out, in 
different combinations (Table 17). For cells mimicking the genetic features of 
oligodendroglioma, the conditional Idh1R132H mice were crossed with Cic floxed mice with 
the inducible Cre-recombinase system. All NSCs were prepared on day P1 and cultured under 
standard NSC conditions. 
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Table 17. Established main neural stem cell cultures and their inherent genotypes. 
C = conditional allele, T = transgenic allele.  
Idh1R132H 
genotype 
ROSA-
CreERT2 
genotype 
p53 
genotype 
Cic 
genotype 
C/+ T/+ - - 
C/+ +/+ - - 
+/+ T/+ C/C - 
+/+ +/+ C/C - 
C/+ T/+ C/C - 
C/+ +/+ C/C - 
+/+ T/+ - C/C 
+/+ +/+ - C/C 
C/+ T/+ - C/C 
C/+ +/+ - C/C 
 
3.2.1 Induction of genetic alterations and validation of established cell lines 
For induction of genetic alterations, 1 µM 4-Hydroxytamoxifen (4-OHT) was added to the 
culture medium 24 hours after passaging to induce Cre-recombination. 4-OHT treatment leads 
to heterozygous expression of mutant Idh1R132H alone or concomitant the knock-out of Tp53 
or Cic. To make sure that the time for recombination is sufficient, 4-OHT was left in the 
culture medium for one week. In case of Cic knock-out cells, treatment with 4-OHT was 
repeated once after the first week, because of incomplete recombination after single treatment. 
Being able to compare effects of the induced genetic alterations, non-inducible control cells 
carrying the same floxed alleles but lacking Cre-recombinase, were included for all 
experiments. Finally, genotypes were validated with SDS-PAGE and Western Blot to ensure 
successful and complete induction. Western blot analysis using the Idh1R132H-mutant specific 
antibody reveals that inducible cells express the conditional knock-in mutation Idh1R132H, 
whereas controls lack the inducible expression. Tp53 knock-outs are confirmed with the 
respective antibody (Figure 11 A). To further validate the successful induction of both genetic 
alterations, immunohistochemistry was performed with the same antibodies (Figure 11 B). 
Application of these specific antibodies clearly shows that induction by 4-OHT was 
successful. 
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Figure 11. Validation of Idh1R132H p53-/- cells. A Western Blot results confirming the 
presence of Idh1R132H mutated protein and Tp53 knock-out of the respective cell lines and 
controls after 4-OHT treatment. B Immunohistochemical staining against the Idh1R132H 
mutation reveals a cytoplasmic signal of the induced spheres only, indicating that 
recombination was successful. Staining against p53 shows a strong nuclear signal in control 
cells, whereas it is barely seen after induction of the knock-out.  
 
Reliable expression signals of Cic protein could not be achieved with all antibodies tested. 
The combination of the wet-blot method, the optimal primary antibody concentration and 
development with a chemiluminescent secondary antibody, leads to reliable detection of Cic 
at 164 kDa (Figure 12 A). 
 
Immunohistochemistry with the same antibodies further supports the successful knock-out of 
Cic in combination with or without the Idh1R132H mutation (Figure 12 B). Cic protein shows 
strong cytoplasmic staining, which almost completely vanishes in Cic-/- cells. Cic knock-out is 
also detectable on RNA level. Cic coding cDNA is not detectable in Cic-/- cells in comparison 
to controls (Figure 12 C). 
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Figure 12. Validation of Idh1R132H Cic-/- cells. A Western Blot results confirming the 
presence of Idh1R132H mutated protein and Cic knock-out in the respective cell lines and 
controls after two treatments with 4-OHT. Mutation-specific antibodies were used for 
detection after wet-blotting on a nitrocellulose membrane. B Immunohistochemistry shows 
that the cytoplasmic signal of Cic is not detectable anymore in knock-out cells. C Results of a 
reverse transcription PCR with primers spanning Exon 10 and 11, indicating the knock-out of 
Cic on RNA level. 
 
3.3 Functional characterization of Idh1R132H p53-/- NSCs: short-term effects 
The following chapter summarizes the results of the functional characterization of newly 
established cell lines harboring an Idh1R132H mutation with or without a knock-out of Tp53. 
The findings are related to cell lines with alterations induced and validated two weeks before 
the start of the experiments, which will be referred to as short-term. 
 
3.3.1 Cell viability 
An increase of cell viability of induced cells could not be observed. Experiments show that 
the induction of the Idh1R132H mutation in inducible cell lines and subsequent production of 2-
HG decreases cell viability up to 44.3 ± 20.2%, compared to respective controls (Figure 13 
A). In line with this, measurements of cell viability across 5 days show a decreased slope of 
the growth curve of Idh1R132H mutated cells compared to controls. Normalized to control on 
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day 5, Idh1R132H mutated cells grow on average 7.8% per day. In contrast, control cells have a 
growth increase of 18.7% daily (Figure 13 B). The cell number after induction of both 
alterations is slightly increased compared to Idh1R132H alone, 70.3 ± 9.8% vs. 44.3 ± 20.2%. 
This is however still a significant decrease compared to controls. The proliferation of p53-/- 
cells is 58.6 ± 23.8% compared to control cells (Figure 13 A). The slope of the growth curve 
of p53-/- cells is slightly decreased (11.6%) compared to respective controls (19.4%). Same 
observations can be made for double mutant cells that also have a decreased growth behavior 
compared to controls (12.8% vs. 19.2% daily). 
 
 
 
Figure 13. Induction of Idh1R132H and subsequent production of 2-HG significantly 
decreases cell viability. A After induction and validation of the genotypes, 5000 cells were 
seeded per well in 96-well plate format and measurements using the CellTiter-Glo 3D Cell 
Viability Assay were performed five days after seeding. Idh1R132H leads to a significant 
decrease of cell viability. A significantly reduced cell number is also observed when a knock-
out of Tp53 was induced alone or in the presence of Idh1R132H, which is however weakened 
compared to Idh1R132H alone. Bar plot of CellTiter-Glo3D assay data, normalized to average 
A 
B 
Results 
 
	 49	
control. B Time series of the CellTiter-Glo 3D Cell Viability Assay reveals that cells 
harboring the Idh1R132H mutation show a distinctive growth disadvantage compared to a single 
knock-out of Tp53 or double mutants. Measurements were performed after 0, 3 and 5 days of 
incubation. Diagram of the CellTiter-Glo 3D Cell Viability Assay, normalized to average 
control on day 5. (Indicated significances: two-sided unpaired students t-test, * = p<0.05, 
n = 3). 
 
3.3.2 Colony formation in soft agar 
Anchorage-independent growth is described as a hallmark of carcinogenesis, as transformed 
cells have the ability to grow independently of a solid surface. The soft agar assay is a well 
described method to check for this potential in vitro and is reported to be one of the most 
important tests to examine malignant transformation in cells (Borowicz et al., 2014).  To 
check for this ability, cells were embedded in soft agar layers and were allowed to grow for 7 
days in 96-well plates before quantification using the resazurin-based CellTiter-Blue Cell 
Viability assay. Experiments indicate that cells harboring an Idh1R132H mutation only, show a 
significantly reduced colony number compared to controls (88.9 ± 3.9%). In contrast, if cells 
harbor a Tp53 knock-out only or in combination with the Idh1R132H mutation, sphere 
formation is slightly increased (107.7 ± 6.3% and 107.1 ± 7.3% respectively) compared to 
controls, and significantly increased to Idh1R132H alone (Figure 14).  
 
 
Figure 14. Induction of Idh1R132H significantly decreases colony formation rate in soft 
agar. Previously induced and validated cell lines were used to seed 2000 cells per well 
embedded in a soft agar matrix in 96-well plates. After 7 days of incubation, measurements 
were performed using the CellTiter-Blue Assay. Idh1R132H alone leads to a significant 
decrease of colony formation. In contrast, if cells harbor a single knock-out of Tp53 or a 
combination of both alterations, there is a tendency towards an increase of colony formation 
rate. Bar plot of the soft agar assay data, normalized to average control after one week of 
incubation. (Indicated significances: two-sided unpaired students t-test, * = p<0.05, n = 3).  
Results 
 
	50	
3.3.3 Analysis of apoptotic proteins 
Differences in the phenotype of single and double mutants can be detected with cell viability 
and colony formation analysis. As a next step, it was aimed to understand these differences. It 
is of interest whether Idh1R132H cells with a decreased proliferative capacity have a higher rate 
of apoptosis. To analyze the level of apoptosis, proteins were analyzed that are described to 
play an important role during later steps of apoptosis. The apoptotic marker proteins cleaved 
Caspase 3 (clC3), cleaved Caspase 7 (clC7) and cleaved Poly (ADP) ribose Polymerase 
(clPARP) were analyzed in Western blot. Results show that apoptosis is slightly increased in 
cells harboring the Idh1R132H mutation compared to controls. Expression of the apoptotic 
proteins clC3, clC7 and clPARP is on average 127.9 ± 138.7%, 320.2 ± 250.4% and 95.1 ± 
51.7%, respectively. In contrast, a knock-out of Tp53 shows a tendency towards a decrease of 
the level of apoptosis. The level of clC3 is 77.5 ± 24.9%, clC7 44.7 ± 6.3% and clPARP 59.5 
± 58.6%. A reduction of apoptosis could also be observed in double mutant cells, which is 
comparable to the Tp53 knock-out cells. Abundance of clC3 protein is reduced to 66.2 ± 
82.6% compared to controls, as well as 65.2 ± 61.1% and 75.7 ± 60.0% for clC7 and clPARP 
respectively (Figure 15).  
 
 
Figure 15. Induction of Idh1R132H slightly enhances levels of apoptosis. Whole cell lysates 
were prepared from 300 µl cell suspension taken from previously induced and validated cell 
lines. After BCA, lysate was subjected to Western blot analysis with antibodies to the 
apoptotic proteins clC3, clC7 and clPARP. Expression of Idh1R132H shows a tendency towards 
an increase of apoptosis. The presence of a knock-out of Tp53, either alone or in combination 
with the Idh1R132H mutation results in a decreased level of apoptosis, observed in all proteins 
tested. Bar plot of the expression of apoptotic proteins, normalized to average control. 
(Indicated significances: two-sided unpaired students t-test, n = 3 and n = 2 for clC3). 
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3.3.4 Production of 2-HG 
The intracellular level of 2-HG produced after induction of the Idh1R132H mutation was 
detected by an enzymatic 2-HG quantification assay. Cells harboring an Idh1R132H mutation 
produce high amounts of 2-HG, which are not altered when Idh1R132H is accompanied by a 
knock-out of Tp53 (Figure 16). Mean intracellular 2-HG concentrations across three replicas 
are 2.7 ± 0.7 mM for single Idh1R132H mutated cells and equally 2.7 ± 0.7 mM for cells 
harboring both alterations. In contrast, p53-/- cells do not produce 2-HG (0.4 ± 0.1 mM), 
which is below the quantification limit of the assay.  
 
 
Figure 16. Cells harboring an Idh1R132H mutation produce 2-HG, which is not altered by 
a concomitant knock-out of Tp53. 300 µl of previously induced and validated cells was 
taken for lysate production and protein concentration was determined with BCA. 2-HG 
concentration produced after induction of the alteration was determined with a 2-HG 
quantification assay. The presence of Idh1R132H alone leads to a significant production of 2-
HG, whereas this is absent in single Tp53 knock-out cells. A combination of both alterations 
induces a similar production of 2-HG, compared to cells with Idh1R132H only. Bar plot of the 
2-HG assay carried out in triplicates, normalized to average control. (Indicated significances: 
two-sided unpaired students t-test, * = p<0.05, n = 3). 
 
3.4 In vivo allograft model 
To test, whether the in vitro results translate into the in vivo situation, the induced NSCs were 
intracranially injected into BALB/c nude mice. BALB/c mice were chosen for these 
experiments as previous research from brain tumor xenograft implantations has shown that 
tumors develop best in these mice (Pusch, 2016).  
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3.4.1 Intracranial injections 
Intracranial injections of NSCs were performed with the main genotypes listed in table 1. 
Mice were anaesthetized with a well-established anesthesia consisting of Ketamin and 
Xylazin. However, this protocol did not lead to the expected success, as almost 50% of mice 
died due to respiratory problems during awakening phase from anesthesia. The anesthesia 
protocol was adjusted as for example not injecting the whole amount the same time, or 
changing the proportion of Ketamin and Xylazin. Given that this did not improve the 
situation, later surgeries were carried out under Isofluran narcosis.  
 
3.4.2 General problems with immunodeficient mice during the time of the experiment 
During the time of the experiment several problems concerning the animals arose. These 
problems did not influence the result of the in vivo study in general, but led to the loss of mice 
and decreased the final number of animals that were alive until termination of the experiment 
(Table 18). The loss was mainly due to health issues caused by inbreed problems, the 
observation period of one year and different types of infections, such as an abscess of the eye.  
 
Table 18. Overview about the different groups of mice implanted with the respective 
genetically altered NSCs. The first number is related to the mice that were initially 
implanted, whereas the number in brackets is related to mice that took part in all MRI screens. 
 
 
 
 
Genotype injected NSCs 
Number of mice (alive until termination of the 
experiment) 
IdhR132H  6 (4) 
IdhR132H control 6 (0) 
p53-/- 6 (3) 
p53-/- control 6 (2) 
IdhR132H p53-/- 10 (5) 
IdhR132H p53-/- control 6 (1) 
Cic-/- 6 (6) 
Cic-/- control  6 (3) 
IdhR132H Cic-/-  6 (6) 
IdhR132H Cic-/- control 6 (1) 
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3.5 Functional characterization of Idh1R132H p53-/- NSCs: long-term effects 
After intracranial injections of the induced NSCs into immunodeficient mice, cells were 
further cultivated for six months. This should show whether the Idh1R132H mutation has an 
effect across a long-term, as this mutation is known to influence epigenetic processes that 
might take more time until effects are measurable. To be able to better compare the effects of 
long-term cells to cells shortly after initial induction, each figure additionally shows a 
transparent figure of the short-term result in the following paragraph. 
 
3.5.1 Cell viability 
After a cultivation period of sixth months, it was first checked whether long-term induction of 
the alterations changes the proliferative potential of the cells by using the ATP-based Cell 
Titer-Glo 3D Cell Viability assay, as described above. The growth disadvantage observed in 
newly induced Idh1R132H cells alone, is almost abrogated after cultivation for several months 
(44.3 ± 20.2% vs. 70.4 ± 34.0% after long-term cultivation). A knock-out of Tp53 shows 
comparable results to Idh1R132H mutated cells, as the relative proliferation is 72.2 ± 35.7% 
compared to controls. Surprisingly, Idh1R132H mutation with a concomitant knock-out of Tp53 
leads to a significantly enhanced proliferation compared to Idh1R132H alone (133.9 ± 26.0% vs. 
70.4 ± 34.0%; Figure 17 A). A significant difference could also be observed between the 
knock-out of Tp53 and double mutants (72.2 ± 35.7% vs. 133.9 ± 26.0%). Analysis of the 
growth behavior of these cells shows that there is a tendency towards a decrease of the 
relative proliferation of Idh1R132H cells across time. Compared to controls (18.6%), mutated 
Idh1 cells have a growth behavior of 11.3% daily. The induction of a Tp53 knock-out across a 
long term does not significantly alter the slope of the growth curve compared to their 
respective controls (14.3% vs. 19.5%). In contrast, cells harboring both genetic alterations 
exhibit a tendency towards a steeper growth curve with a slope of 25.3% per day, compared to 
respective controls (19%). The course of the growth curve is in line with the cell number 
measured on day 5 of the experiment, as double mutants have an enhanced proliferation rate 
(Figure 17 B). 
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Figure 17. Idh1R132H cells with a concomitant knock-out of Tp53 develop an increased 
proliferative potential after six months of induction. A Six months after initial induction, 
5000 cells were seeded per well in 96-well plates and measurements using the CellTiter-Glo 
3D Cell Viability Assay were performed after five days of incubation. One single alteration 
either Idh1R132H or p53-/- does not alter cell viability, if cells were cultivated for 6 months. 
Double mutants have an enhanced proliferation, which is not observed after initial induction 
of the alterations. Bar plot of CellTiter-Glo3D assay normalized to average control.  
B Consecutive measurements of the CellTiter-Glo 3D Cell Viability Assay on day 0, 3 and 5 
reveal that cells harboring the Idh1R132H mutation show a flattened growth curve compared to 
controls. A single knock-out of Tp53 does not alter growth curve, whereas double mutants 
grow faster compared to controls. Diagram of the CellTiter-Glo 3D Cell Viability Assay 
shows proliferation normalized to average control on day 5. (Indicated significances: two-
sided unpaired students t-test, * = p<0.05, n = 3). 
 
3.5.2 Colony formation in soft agar 
Long-term cells were also embedded in soft agar as described above and colony formation 
was analyzed after 7 days. Cells harboring the Idh1R132H mutation show a significantly 
reduced colony number compared to controls (36.3 ± 32.1%). p53-/- cells do not exhibit an 
A 
B 
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altered growth capacity in soft agar matrix compared to controls (85.9 ± 11.7%). In contrast, 
if the knock-out of Tp53 is combined with Idh1R132H, cells show an enhanced ability to form 
colonies in soft agar (Figure 18). The relative colony number of double mutants is 326.3 ± 
183.7% compared to the respective control cells. Cells harboring both alterations across a 
period of 6 months, show a more tumorigenic phenotype with an increased proliferative 
potential, compared to newly induced cells. 
 
Figure 18. Idh1R132H p53-/- cells show an enhanced colony formation rate six months after 
initial induction. Long-term cell lines were embedded in soft agar matrices in a density of 
2000 cells per well. CellTiter-Blue Assay was performed seven days after seeding of the cells. 
Idh1R132H alone leads to a significant decrease of colony formation compared to controls. If 
cells harbor a single knock-out of Tp53 colony formation rate is not altered. In contrast, a 
combination of both alterations leads to an enhanced formation of colonies in soft agar. Bar 
plot of the soft agar assay shows colony number normalized to average control after one week 
of incubation. (Indicated significances: two-sided unpaired students t-test, * = p<0.05, n = 3). 
 
3.5.3 Analysis of apoptotic proteins 
The above described difference in the proliferative capacity between single and double 
mutants could be achieved by reduced levels of apoptosis in cells harboring both alterations. 
To investigate this in more detail, Western blot experiments were performed to analyze 
expression of late apoptotic proteins. Decreased levels of apoptotic proteins could be detected 
in single Idh1R132H mutant cells, which is 45.5 ± 17.3% for the expression of clC3, 57.6 ± 
20.1% for clC7 and 43.4 ± 8.9% for the expression of clPARP. Levels of apoptosis are also 
decreased in cells with a single knock-out of Tp53, which is on average a decrease to 31.3 ± 
17.0% of clC3 expression, compared to controls. Expression of clC7 and clPARP is reduced 
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to 34.3 ± 17.4% and 39.6 ± 17.7% respectively. Interestingly, cells that harbor a combination 
of both alterations show increased clC3 expression levels of 158.8 ± 12.7%, compared to 
controls (Figure 19). clC7 and clPARP expression is also increased to 150.2 ± 36.4% and to 
127.3 ± 31.5% respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Apoptosis is strongly increased in long-term cells harboring both Idh1R132H 
and p53-/-. Whole cell lysates were prepared from 300 µl cell suspension taken from cell lines 
induced six months beforehand. After determining the protein concentration with BCA, lysate 
was subjected to western blot analysis with antibodies to the apoptotic proteins clC3, clC7 
and clPARP. Expression of Idh1R132H or p53-/- alone decreases the expression of all apoptotic 
proteins tested. p53-/- in an Idh1R132H background significantly increases the level of apoptosis, 
reflected in an enhanced expression of clC3, clC7 and clPARP. Bar plot of the expression of 
apoptotic proteins, normalized to average control. (Indicated significances: two-sided 
unpaired students t-test, n = 4). 
 
3.5.4 Analysis of cell cycle markers in long-term cells 
Being able to investigate the increase of the proliferative capacity in more detail, long-term 
cells were stained with antibodies specific for cell cycle markers. After verification of the 
antibodies on control brain tissue, stainings of mutated cell lines were always compared to 
non-inducible ones (Figure 20 A). To do so, spheres were embedded in a paraffin block, 
histological slices prepared and stained with haematoxylin and eosin (HE). With this control 
staining, the presence and morphology of all embedded cell lines was verified (Figure 20 B). 
Subsequently, immunostainings were performed with antibodies to the antigen Ki-67 and 
phosphohistone H3 (pHH3). More Ki-67 positive cells can be detected in Idh1R132H p53-/- cells 
compared to controls, indicating that more cells are in G1, S, G2, and mitosis. pHH3, a marker 
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for mitotic index, shows an increased number of positive cells in Idh1R132H p53-/- cells. Taken 
together, both immunohistochemistry markers confirm that more cells with both genetic 
alterations are proliferating, which is in line with the results described before.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Immunohistochemistry of cell cycle markers. A Overview of a HE staining of 
all cell lines on one slide. Each circle represents the embedded spheres of one particular cell 
line. B Immunostainings of Idh1R132H p53-/- embedded spheres reveals a strong cytoplasmic 
staining of Ki-67 and pHH3, pointing towards an enhanced proliferative capacity compared to 
controls. 
 
3.5.5 Analysis of epigenetic effects of Idh1R132H 
It is known that mutant Idh1 has various effects on epigenetics, e.g. DNA methylation. 
Amongst others, Idh1R132H induces the inhibition of TET enzymes, regulating the conversion 
of DNA 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). Further, it was shown 
that induction of Idh1R132H decreases the level of 5hmC, thereby altering gene regulation. 
Dotblot experiments were performed in order to investigate whether induction of the genetic 
alterations has an influence on DNA methylation six months after initial induction. To do so, 
DNA samples from different cell lines were blotted onto a nitrocellulose membrane and 
immunostainings against 5mC and 5hmC were carried out.  Expression of mutant Idh1 alone 
shows a tendency towards enhanced levels of both 5mC and 5hmC (111.7 ± 29.5% and 125.6 
± 27.0%, respectively). A knock-out of Tp53 does not alter the abundance of 5mC (100.0 ± 
22.9%), whereas levels of 5hmC are slightly decreased, with a signal of 79.1 ± 18.0%. In 
contrast, in Idh1R132H p53-/- cells, there is a tendency of enhanced levels of both 5mC and 
5hmC.  Analysis of the dotblot membranes after staining against 5mC displayed a level of 
  Anti- Ki-67       Anti- pHH3 
control 
induced 
Idh1R132H 
p53-/- A B 
Results 
 
	58	
134.6 ± 51.6% compared to the respective control cells and a 5hmC level of 120.4 ± 33.9% 
(Figure 21). 
 
Figure 21. Induction of Idh1R132H does not significantly alter DNA methylation. DNA was 
extracted from genetically altered cell lines induced six months beforehand. DNA 
concentration was determined with Qubit before it was blotted onto a nitrocellulose 
membrane with a dotblot device. Expression analysis of epigenetic markers was done with 
antibodies to 5mC and compared to 5hmC in induced cell lines and controls. Expression of 
Idh1R132H alone shows a tendency towards an increase of both 5mC and 5hmC. A knock-out of 
Tp53 does not alter the expression of 5mC, whereas 5hmC is slightly enhanced. p53-/- in an 
Idh1R132H background shows a tendency of enhanced level of both epigenetic markers. Bar 
plot reflects the expression of 5mC and 5hmC, normalized to average control. (Indicated 
significances: two-sided unpaired students t-test, n = 3). 
 
3.5.6 Production of 2-HG 
The production of 2-HG was also measured in cells harboring the alterations across a period 
of more than six months. Surprisingly, cells harboring the Idh1R132H mutation either alone, or 
in combination with a knock-out of Tp53 do not produce 2-HG anymore. As depicted in 
figure 22, the intracellular 2-HG concentration detected is even below the quantification limit 
of the 2-HG enzymatic assay. Across three replicas, average 2-HG levels are 0.3 ± 0.2 mM 
for cells harboring the Idh1R132H mutation only and 0.4 ± 0.3 mM for double mutants. 2-HG 
measurements of the supernatant revealed that 2-HG does not accumulate extracellularly 
(Supplement Figure 1). Single Tp53 knock-out cells do not produce 2-HG, which is on 
average 0.5 ± 0.5 mM. These results show that the cells harboring the Idh1R132H mutation lost 
their ability to produce 2-HG across time. 
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Figure 22. Long-term Idh1R132H mutated cells completely lose their ability to produce 2-
HG. 300 µl of cell suspension from long-term cell lines was taken for lysate production and 
protein concentration was determined with BCA. 2-HG concentration was determined with a 
2-HG quantification assay. Production of 2-HG is absent in cells harboring the Idh1R132H 
mutation either alone or in combination with a knock-out of Tp53, which is only observed in 
long-term cells. The appearance of p53-/- alone does also not result in the production of 2-HG. 
Bar plot of the 2-HG assay carried out in triplicates. (Indicated significances: two-sided 
unpaired students t-test, * = p<0.05, n = 3). 
 
3.6 Loss of Idh1R132H in long-term cell lines 
The loss of the ability to produce 2-HG in long-term cultures pointed towards an alteration of 
the mutational status of the cells. To investigate this in more detail, the presence of mutant 
Idh1 protein was analyzed. Mutant Idh1 protein cannot be detected in long-term. In contrast, 
the knock-out of Tp53 is still detectable in all cell lines, no matter if single mutant or in 
combination with Idh1R132H. Given the fact that all cell lines were validated after initial 
induction, the cells must have lost the Idh1R132H mutation after several weeks. In order to 
investigate this in more detail, cells were freshly induced and checked for the presence of the 
Idh1R132H mutation with concomitant production of 2-HG and also the knock-out of Tp53. The 
loss of the Idh1R132H mutation can be followed by measuring 2-HG levels. It starts with a 
tendency towards a decrease of 2-HG one month after application of 4-OHT, from 14.5 ± 2.7 
mM to 12.4 ± 0.2 mM 2-HG. This drop steadily continues across a period of 10 days, where 
only 1.5 ± 0.1 mM of 2-HG can be detected intracellularly. In parallel to the 2-HG 
measurements, immunohistochemistry was performed on embedded cells with the antibody to 
Idh1R132H. Stainings indicate that a lower number of cells is positive for Idh1R132H 30 days 
after initial induction, matching the decreasing concentration of 2-HG. 50 days after 
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induction, 2-HG levels are below detection limit (0.6 ± 0.1 mM), which is accompanied by a 
complete loss of Idh1 mutant protein (Figure 23 A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Loss of the Idh1R132H mutation. A After protein extraction, Western blot analysis 
with the antibody to Idh1R132H reveals a lack of mutant Idh1 protein more than 6 months after 
induction with 4-OHT. However, expression of mutant Idh1 is still detectable in cells that 
were newly induced. The status of Tp53 is not altered in both long- and short-term cultures. 
Staining against b Actin serves as a loading control. B Follow-up 2-HG screening of freshly 
induced cells starts directly after 4-OHT treatment. 2-HG level steadily decreases after 30 to 
40 days, which is accompanied by a drop in the cytoplasmic expression signal of Idh1R132H. 
(Indicated significances n = 3) 
 
To understand the loss of Idh1R132H in more detail, all cell lines were re-genotyped with 
primers P259/789 binding to lox P site 1 and to the exon containing the knock-in Idh1R132H 
mutation (Supplement Table 2). Experiments confirm that the chromosomal loss is a general 
phenomenon in all long-term cultures that harbored the Idh1R132H conditional allele, because 
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genotyping did not yield a PCR product in most cases, indicating that the loss encompasses a 
large chromosomal region. Only the PCR on DNA from cell line #13 leads to a PCR product 
that shifts from the normal Idh1R132H knock-in at 867 bp to clearly lower product, suggesting a 
small chromosomal loss (Figure 24 A). In the following, this PCR product was used for 
sequencing analysis with primers P259 and P789. Sequencing shows a loss spanning a large 
region encompassing lox P site 1 up until Exon 3 (Figure 24 B). This loss leads to a 
frameshift mutation, finally causing the loss of mutant Idh1 protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Analysis of the chromosomal loss of Idh1. A Re-genotyping of Idh1R132H 
mutated cell lines reveals that the DNA of long-term cells show a shift of the PCR product 
towards 400 bp. Cells that previously lost the Idh1R132H mutation exhibit a smaller PCR 
product compared to newly induced cells. B Sequencing alignment of the PCR product after 
genotyping of a cell line that lost the Idh1R132H mutation. Black arrows indicate the whole 
region from lox P site 1 until Exon 3 that is not detectable anymore and thus cause the loss of 
mutant Idh1 protein. 
 
3.6.1 Loss of Idh1R132H in vivo? 
After confirmation of the loss of the Idh1R132H mutation in vitro, the question arose whether 
the same phenomenon can be observed in vivo as well. To answer this question, 
immunohistochemistry was performed. Slices were taken from a mouse that died two months 
after intracranial injections of Idh1R132H mutated cell lines with a concomitant knock-out of 
Tp53. First, the depth of the slice was verified with a HE staining to make sure that the area of 
implantation was in focus. Subsequently, immunohistochemistry was performed with the 
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specific antibody to Idh1R132H. Results clearly indicate that the implanted cells are still 
present, carry the Idh1R132H mutation and invade the surrounding brain tissue (Figure 25). This 
result shows that there is a difference between the in vivo and the in vitro situation. 
 
Figure 25. Positive Idh1R132H staining two months after intracranial injection.  
Immunostainings of Idh1R132H p53-/- implanted NSCs reveals a positive signal for Idh1R132H in 
the surrounding brain parenchyma of the area of injection. 
 
3.7 MRI monitoring of BALB/c nude mice after intracranial injections 
Implanted mice were monthly monitored with a 1.5 T MRI scan. Usually, T2-weighted 
images were taken, whereas a T1-weighted recording was performed subsequently, if lesions 
were observed. During the first months of the in vivo study there was no indication of any 
space-consuming lesions in the area of implantation. However, 8 months post-surgery there 
are first indications for tumor growth in the right frontal cortex, observed in mice implanted 
with Idh1R132H p53-/- cells (Figure 26 A, B). Tumor-like lesions are observed in 2/5 mice 
implanted with Idh1R132H p53-/- cells, which is 2/3 mice implanted the same day from the same 
batch of cells. Calculated volumes of the lesions observed in T2-weighted measurements are 6 
and 1.8 µl. Injection of contrast enhancing agent shows that lesions do not accumulate the 
substance, which is an often-observed phenomenon in murine glioma models (DKFZ, 2017). 
In addition, 1/3 mice intracranially injected with NSCs harboring a knock-out of Tp53, a 
control cell line, develop a lesion of 4.9 µl measured in the T2 sequence. This tumor does 
accumulate the contrast enhancing agent after injection and calculated volume after the T1-
weighted sequence is 9.9 µl (Figure 26 C, D). 
 
In contrast to mice injected with Idh1R132H p53-/- NSCs, mice implanted with Idh1R132H Cic-/- 
NSCs do not show any indication for tumor formation across the course of the study. This is 
also true for mice with Cic-/- cells. 
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Figure 26. Murine glioma allograft generated in athymic BALB/c nude mice eight 
months after intracranial injections. A T2-weighted MRI of a mouse brain implanted with 
Idh1R132H p53-/- cells showing a lesion with a volume of 6 µl. B A smaller volume of 1.5 µl is 
measured in another mouse injected with Idh1R132H p53-/- NSCs, under comparable T2-
weighted settings. C Picture taken from a T2-weighted sequence of a mouse that was 
implanted with single p53-/- cells eight months before. The volume of this lesion is 4.9 µl.  
D T1-weighted recording of the same mouse, indicating that the tumor accumulated the 
contrast enhancing agent. (Red arrows indicate the area of the lesion). 
 
MRI signals and the calculated volumes of the lesions varied in the following months, which 
might be due to beginning formation of a tumor and the subsequent infiltrative growth 
characteristic of gliomagenesis. Thus, mice were further screened with MRI monthly. T2-
weighted tumor volume of the first Idh1R132H p53-/- mouse decreases from 6 µl to 1.5 µl 
(Figure 27 A). The same is observed in the second mouse (Figure 27 B). Due to an already 
small volume of 1.8 µl, the lesion is not clearly visible anymore, one month later. In contrast, 
the only mouse implanted with p53-/-, still had a detectable lesion in the next MRI. However, 
the volume of the lesion also dropped from 4.9 µl to 2.3 µl, calculated after T2-weighted MRI 
(Figure 27 C). T1-weighted images confirm the shrinkage from 9.9 µl to 2.6 µl (Figure 27 D). 
This lesion started to progress after ten months, which is in contrast to mice injected with 
Idh1R132H p53-/- NSCs (Figure 27 E). 
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Figure 27. Decreasing volume of the lesions observed during MRI screen nine months 
after implantation. A T2-weighted MRI of a mouse brain implanted with Idh1R132H p53-/- 
cells nine months previously, showing a lesion with a volume of 1.5 µl, which has a volume 
of 6 µl during the last scan. B Another mouse injected with Idh1R132H p53-/- NSCs, has a 
volume of 1.8 µl eight months after implantation, whereas it is not clearly detectable anymore 
after nine months. C T2-weighted image of a mouse that was implanted with single p53-/- cells 
nine months before. The volume of this lesion is 2.3 µl, whereas it is 4.9 µl after eight months. 
D T1-weighted image of the same mouse, indicating that the tumor accumulates the contrast 
enhancing agent. The calculated size of the lesion after T1 recording is 2.6 µl. E Table 
depicting the course of tumor formation. Mice injected with Idh1R132H p53-/- NSCs show a 
decreasing volume. Tumor growth in the p53-/- injected mouse also first decreases but then 
reaches a stable progress observable in later MRI scans (A-D, red arrows indicate the area of 
the lesion). 
 
3.7.1 9.4 T scans 
Due to the low resolution of the 1.5 T MRI scans, one could not exclude that there is no tumor 
anymore. To validate this, a 9.4 T MRI with a better spatial resolution was used for 
recordings before termination of the experiment. T2-weighted images were taken from each 
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mouse, whereas a T1-weighted recording was only performed with the animals, which 
showed lesions in the 1.5 T MRI. The results are not comparable to the 1.5 T MRI screens at 
eight months after implantation. The 9.4 T images further confirm that there are no visible 
lesions 12 months after surgeries. However, 9.4 T data depict the area of implantation in the 
frontal cortex even one year after intracranial injections. Amongst the puncture caused by the 
injection needle in the cortex, images show a hole further below the implantation. These holes 
can only be observed in 3/5 mice implanted with double mutant cells, in 2/4 mice with 
Idh1R132H cells and in 1/2 mouse with cells harboring a single knock-out of Tp53 (Figure 28). 
Interestingly, the animals showing a lesion in 1.5 T MRI scans were amongst those. 
Comparable to 1.5 T data, mice with Cic-/- as well as Idh1R132H Cic-/- NSCs do not show any 
signs of a lesion in the area of implantation.  
 
3.8 Immunohistochemistry 
To validate the in vivo model immunohistochemistry was used. First a HE control staining 
was prepared to validate the correct position of the slice, the area of implantation. One year 
after surgeries, the puncture was not clearly visible in all cases. Because of this, anatomical 
orientation was used to find the correct depth/position. Additionally, stainings of mice 
implanted with induced cell lines were always compared to those with non-inducible cell 
lines. After the correct identification of the area of implantation by HE staining, subsequent 
slices were stained with antibodies to detect Idh1R132H. To also detect non-inducible control 
cells, an antibody to forkhead box protein N1 (Foxn1) was used. BALB/c nude mice are 
deficient for this gene, which is responsible for the hairless and athymic phenotype. Implanted 
cells are derived from Bl6/N mice and by this, are positive for Foxn1. Although, different 
concentrations and pretreatments were tested, only neurons showed a reproducible positive 
staining. But neurons are known for false positive staining in immunohistochemistry, which 
could be confirmed in the parallel stained control slices. 
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Figure 28. 9.4 T scans indicate the injection puncture 12 months after intracranial 
injections. T2-weighted images represent one example per group of mice with the specified 
NSCs injected. A lesion due to tumor formation cannot be detected in all mice imaged. (- 
means that no mice of the respective group were still alive during the 9.4 T MRI scan)  
 
To be able to anyway detect the implanted cells, an antibody to Cre was used. For the 
validation of the antibody, slices of the mouse were taken that died two months after surgery, 
in which the Idh1R132H staining was already positive and the injection puncture is clearly 
visible (Figure 29 A, B). The presence of the Idh1R132H positive cells was confirmed by 
positive Cre recombinase staining (Figure 29 B, C). The successful application of the Cre 
antibody allowed using it on slices taken from mice that were alive until termination of the 
experiment. The challenge was to detect the implanted cells in exactly these mice as the 
injection point is mostly overgrown one year after surgery. 
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Figure 29. Two months after intracranial injections Idh1R132H positive cells start to 
invade the brain parenchyma. A Image of a HE overview staining of a mouse brain 
implanted with Idh1R132H p53-/- cells two months previously. Black box indicates the area of 
injection. B 10x magnification of this area stained with HE for morphological analysis. 
Application of an antibody specific to Idh1R132H shows that injected cells do not lose the 
mutation in vivo and start to invade the brain. An antibody to Cre-recombinase additionally 
confirms presence of the injected cells. C 40x magnification of the red framed areas indicated 
in A.  
 
Next, slices from a mouse that was also intracranially injected with NSCs harboring both, the 
Idh1R132H mutation and a knock-out of Tp53, but lived until termination of the experiment, 
was analyzed. This mouse was one of the mice in which a lesion in the right frontal cortex 
could be observed in MRI images 8 months after implantation.  
 
The Cre antibody was applied to detect the injected cells. No positive signal for Cre could be 
detected (Figure 30 B) in the area where the cells were originally implanted. After careful 
examination of the whole brain slice, cells with a positive cytoplasmic signal were detected in 
different regions. These cells are located in the corpus callosum and more lateral located brain 
areas of the right hemisphere (Figure 30 C, D). 
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Figure 30. Two months after intracranial injections Idh1R132H positive cells start to 
invade the brain parenchyma. A Image of a HE overview staining of a mouse brain 
implanted with Idh1R132H p53-/- cells twelve months previously. Upper black box indicates the 
area of injection. Right black box represents the actual position of the injected cells in the 
right hemisphere. B 10x magnification of the injection area stained with HE for 
morphological analysis. Staining against Idh1R132H and Cre-recombinase indicates that 
injected cells are not located in this area. C 10x magnification of an area in the right 
hemisphere with Idh1R132H positive cells, showing presence of the injected cells. Cells in the 
same area also have an enhanced expression signal for Cre-recombinase. D 40x magnification 
of the red framed areas indicated in C. 
 
3.9 In vitro analysis of a Cic knock-out alone and in an Idh1R132H background 
In the following chapter the effects of a Cic knock-out with or without an additional Idh1R132H 
mutation will be described, which is a combination commonly found in oligodendroglioma. 
All experiments were carried out after two treatments with 4-OHT, which takes two weeks 
and subsequent validation of the cell lines. The effects of the Idh1R132H mutation is not 
considered here, as the functional validation of Idh1R132H alone is described in chapter 3.3. 
 
3.9.1 Cell viability 
Proliferation analysis reveals that cells harboring a single knock-out of Cic have a 
significantly increased cell viability compared to the respective controls. The cell number of 
Cic-/- cells is increased to 203.0 ± 72.9% 5 days after incubation. Interestingly, if the knock-
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out of Cic appears in an Idh1R132H background, cell viability is not altered (96.7 ± 20.7% from 
control; Figure 31 A). Same can be observed when measurements are performed in time 
series on day 0, 3 and 5. Measurements reveal that Cic-/- cells have a steeper growth curve 
compared to controls (35.9% vs. 19%, daily). In contrast, double mutant cells show a growth 
behavior comparable to their respective controls. The growth curve of Idh1R132H Cic-/- cells 
have a slope of 14.5% daily, compared to controls (19.4%; Figure 31 B). Based on these 
results, the enhanced cell viability of single Cic knock-out cells is inhibited by a concomitant 
Idh1R132H mutation, which is in line with the above described results on Idh1R132H alone. 
 
 
Figure 31. A knock-out of Cic significantly increases cell viability. A Genetically altered 
cells were validated prior to seeding of 5000 cells in 96-well plates and measurements using 
the CellTiter-Glo 3D Cell Viability Assay were performed five days after seeding. Induction 
of Cic-/- leads to a significant increase of cell viability compared to respective controls. The 
combination of both alterations, Cic-/- and Idh1R132H does not alter cell viability. Bar plot of 
CellTiter-Glo3D assay, normalized to average control. B Time series of the CellTiter-Glo 3D 
A 
B 
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Cell Viability Assay reveals that cells harboring a knock-out of Cic have a growth advantage 
compared to a combination with Idh1R132H. Measurements were performed after 0, 3 and 5 
days of incubation. Diagram of the CellTiter-Glo 3D Cell Viability Assay measured on three 
time points, normalized to average control on day 5. (Indicated significances: two-sided 
unpaired students t-test, * = p<0.05, n = 3). 
 
3.9.2 Colony formation in soft agar 
Next, it was also investigated whether the knock-out of Cic has an effect on the cells ability to 
form colonies under growth aggravated circumstances. Results show that a knock-out of Cic 
does not affect colony formation, compared to the control cells (94.1 ± 8.4% from control). 
Further, if the knock-out of Cic is accompanied by the Idh1R132H mutation, the cells ability to 
form colonies is not significantly altered as well. The average colony formation rate of double 
mutants compared to controls is 96.3 ± 10.3% (Figure 32). These results show that the 
genetically altered cells are able to grow under growth aggravated circumstances. 
 
 
Figure 32. Induction of Cic-/- does not affect colony formation rate in soft agar. 
Previously induced and validated cell lines were seeded in a density of 2000 cells per well in 
a soft agar matrix. Measurements were performed using the CellTiter-Blue Assay after 7 days 
of incubation. Cic-/- alone, or in combination with Idh1R132H does not alter colony formation in 
soft agar. Bar plot of the soft agar assay, normalized to average control after one week of 
incubation. (Indicated significances: two-sided unpaired students t-test, * = p<0.05, n = 3) 
 
3.9.3 Effects on epigenetics 
As described above, induction of Idh1R132H has an effect on epigenetics, which might be 
affected by an additional knock-out of Cic. Thus, the aim was to investigate whether 
Idh1R132H and Cic-/- influence abundance of 5mC and 5hmC. As effects on epigenetics might 
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not be detectable after initial induction, cells were cultivated for six months prior to 
experiments. DNA was extracted as described above and subjected to dotblot analysis on a 
nitrocellulose membrane with antibodies to 5mC and 5hmC. A knock-out of Cic alone does 
not influence either levels of 5mC and 5hmC. When compared to controls, the abundance of 
5mC in Cic knock-out cells is 81.2 ± 31.7% and 5hmC 80.1 ± 20.8%. Cic-/- in an Idh1R132H 
background also does not alter levels of 5mC and 5hmC significantly. 5mC expression is 87.7 
± 6.9%, whereas 5hmC expression is 90.1 ± 7.9% from control (Figure 33). These results 
show that a knock-out of Cic with or without the presence of Idh1R132H does not alter DNA 
methylation by regulating the ratio of 5mC and 5hmC.  
 
Figure 33. The presence of Cic-/- with or without Idh1R132H does not alter DNA 
methylation. DNA was extracted from genetically altered cell lines induced six months 
beforehand and concentration determined with Qubit. Samples were blotted onto a 
nitrocellulose membrane with a dotblot device. Expression analysis of DNA methylation 
markers was carried out with antibodies to 5mC and compared to 5hmC in induced cell lines 
and controls. Expression of Cic-/- alone or in an Idh1R132H background does not alter either 
5mC or 5hmC levels. Bar plot reflects the expression of 5mC and 5hmC, normalized to 
average control. (Indicated significances: two-sided unpaired students t-test, * = p<0.05, 
n = 2). 
 
3.9.4 Production of 2-HG 
As cells harboring an Idh1R132H mutation produce remarkable amounts of 2-HG, the next aim 
was to investigate whether the production of 2-HG is influenced by a concomitant knock-out 
of Cic. Cells harboring the knock-out of Cic alone do not produce 2-HG. The values detected 
were below the quantification limit of the assay (0.2 ± 0.1 mM). In contrast, cells harboring 
an Idh1R132H mutation and a knock-out of Cic produce 2-HG concentrations, comparable to 
single Idh1R132H mutated cells (Figure 34). The intracellular concentration of 2-HG measured 
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in these cells is 2.4 ± 1.0 mM. The production of 2-HG in cells harboring both genetic 
alterations does not change across the time of cultivation of the cells, as it does for Idh1R132H 
cells or the combination of Idh1R132H and p53-/-. Those cells show a progressing decrease of 
the production of 2-HG after two months latest. The decrease of 2-HG was accompanied by a 
loss of Idh1R132H. These data show that the knock-out of Cic in Idh1R132H cells induces 
different mechanisms, which distinguishes them from Idh1R132H cells with or without p53-/-.  
 
 
Figure 34. Cic knock-out cells do not produce 2-HG and it does not influence production 
of 2-HG in cells with an additional Idh1R132H mutation. 300 µl of previously induced and 
validated cells was taken for lysate production and protein concentration was determined with 
BCA. 2-HG concentration was measured with a 2-HG quantification assay. Cic-/- cells do not 
produce 2-HG. A combination of both Idh1R132H and Cic-/- leads to release of 2-HG. Bar plot 
of the 2-HG assay carried out in triplicates, normalized to average control. (Indicated 
significances: two-sided unpaired students t-test, * = p<0.05, n = 3). 
 
3.10 PET imaging: IDH1R132H and its relation to epileptogenesis 
The main aim of this project was the development of an in vivo allograft model based on 
IDH1R132H, but in addition this model could also be used to investigate the co-occurrence of 
epileptic seizures in such glioma.  
 
To do so, it is of utmost importance to understand the relation of IDH1R132H and epilepsy. 
First, the question is how to investigate epileptogenesis in mice, as milder types of seizures 
are only barely detectable by behavioral changes. To overcome this problem, the occurrence 
of seizures in mice harboring a glioma was investigated with imaging methods. In the long 
run, this method could be additionally applied to the mouse model based on the IDH1R132H 
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mutation and show whether the induced tumor is accompanied by the development of 
epileptic seizures.  
 
PET/CT scans were performed as described after accumulation of FDG used as a surrogate 
for potential seizure occurrence. For analysis, the mean PET/CT Standardized Uptake Value 
(SUV) was calculated by the animal imaging facility of the DKFZ, which serves as a marker 
for the distribution volume of the radiotracer. The SUV includes the concentration of the 
radioactivity within the region of interest, the amount of radiolabeled FDG and the weight of 
the animal (Kinahan and Fletcher, 2010). Uptake of FDG in the muscle was used as control 
tissue for analysis. Based on the findings that interictal brain activity might be accompanied 
by contralateral hypometabolism, region of interest was set in the left hemisphere as this is 
also not influenced by glucose uptake by the tumor implanted in the right hemisphere. 
 
The experiment was successfully performed with six mice harboring a secondary GBM 
xenograft with IDH1R132H mutation (glioma xenograft w/IDH1R132H), two mice with a primary 
GBM without IDH1R132H mutation (glioma xenograft w/oIDH1R132H) and three mice that were 
implanted with control cells without mutation (control). Imaging was performed when tumor 
volume was about 50 µl observed in MRI images in the right hemisphere.  
 
First PET scans reveal an average SUVmean of 5.3 ± 1.5 in the glioma xenograft w/IDH1R132H 
and 4.1 ± 1.4 in the glioma xenograft w/oIDH1R132H group. The control group has a SUVmean  
of 5.2 ± 0.9 (Figure 35). After initial PET measurements, mice were treated with an 
IDH1R132H specific inhibitor reducing the production of 2-HG, which is believed to be a 
trigger for epileptogenesis due to its structural similarity with glutamate (Kolker et al., 2002; 
Pusch et al., 2017). The idea was to investigate in a subsequent PET recording 24 h later, 
whether FDG uptake is altered and might thus give an indication of prior epileptogenesis. 
PET scans 24 h after inhibitor treatment have an average SUVmean of 6.7 ± 2.4, 6.3 ± 1.9 and 
3.7 ± 0.3 in the glioma xenograft w/IDH1R132H, the glioma xenograft w/oIDH1R132H group and 
the control group respectively. Mice harboring a glioma with IDH1R132H mutation have a 
tendency towards an increase in metabolic activity after treatment with BAY1436032, but it 
was not significant (Figure 35). 
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Figure 35. Suspected epileptogenesis in IDH1R132H glioma mice cannot be observed with 
FDG kinetic analysis. SUVmean of FDG accumulation does not give an indication of 
hypometabolism in the glioma xenograft w/IDH1R132H group as values do not differ between 
groups. No significant effect can be observed after treatment with the IDH1R132H specific 
inhibitor BAY1436032. (Calculated significances: two-sided unpaired students t-test, * = 
p<0.05, n ≥ 2). 
 
On the first day without treatment no hypometabolism can be observed in the glioma 
xenograft w/IDH1R132H and values between groups do not significantly differ.  Likewise, there 
is no significant effect 24 h after treatment with the IDH1R132H specific inhibitor. The results 
indicate that there is no occurrence of epilepsy in mice with implanted glioma. 
 
Furthermore, it can be observed that BALB/c nude mice have an atypical accumulation of 
FDG throughout the whole body. The radiotracer is concentrated mainly in the neck and back 
and only barely in the brain (Figure 36). Normally, it can be assumed that FDG should 
accumulate in the area of tumor growth, which is not seen at all. These results show that PET 
imaging in combination with BALB/c nude mice is not a suitable method to investigate the 
occurrence of epilepsy. 
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Figure 36. PET image of a BALB/c nude mouse with atypical accumulation of FDG. 
Scan of a mouse implanted with a glioma xenograft w/IDH1R132H. Strong FDG accumulation 
can be observed in the thorax, especially in the neck and along the spine. Increased glucose 
uptake is completely missing in the area of implantation in the brain. 
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4 Discussion 
 
The aim of this project was to establish an in vivo allograft model based on neural stem cells 
from mice with different genetic modifications, mimicking molecular alterations in human 
diffuse, IDH-mutant glioma. Generation and validation of these neural stem cells with 
different genetic modifications was successful, but these cells did not show strong 
tumorigenic potential compared to their unmodified counterparts. This could be due to the 
growth behavior of low grade gliomas that also proliferate slowly in the human situation. 
Nevertheless, these cells were implanted in vivo to analyze if the modifications have higher 
tumorigenic potential in vivo. This attempt showed more promising results, as tumor growth 
was visible after eight months. Unexpectedly, these tumors disappeared until the end of the 
observation period of twelve months. In conclusion, the project aim was only partially 
reached, but it delivered data and a suitable model system essential for further understanding 
of the function of the Idh1R132H mutation. 
 
Within this project it was possible to solve the following questions: 
• Is the Idh1R132H mutation sufficient to generate a glioma in a mouse model? 
• Are the common co-occurring mutations in human glioma important for 
gliomagenesis in a mouse model? 
 
Points that need further understanding and for which the established system is the best 
suitable model, are: 
• What makes the Idh1R132H mutation essential in human glioma and why is it not 
required in vitro? 
• Are double-strand breaks the underlying cause for genome instability? When exactly 
is genome instability initiated and is it probably a very early event taking place after 
induction? 
• By which mechanism does the mutation promote its exclusion? Is this a pro-
tumorigenic effect of the Idh1R132H mutation, causing higher mutation rates? 
• What is to be learned from the behavior of these NSCs in vivo? Was the right cell type 
used?  
• What is the effect of 2-HG if it is released in an environment with a normal immune 
system? 
• Why did the tumors diminish after initial growth? 
Discussion 
 
	 77	
In addition to the development towards a more tumorigenic phenotype, cells harboring the 
Idh1R132H mutation either alone, or in combination with a knock-out of Tp53, lost the mutation 
within two months. In fact, this is a very significant observation, as cultivation of cells 
deriving from human gliomas also show the same loss of the Idh1R132H mutation. Thus, these 
findings display important parallels between the human system and the one described in this 
work. 
 
4.1 Effects of Idh1R132H 
As a first attempt, cell viability was analyzed indicating that induction of the Idh1R132H 
mutation significantly decreases the cell number (Figure 37 A). Given the fact that the 
CellTiter-Glo 3D Assay is based on ATP released from viable cells and 2-HG is known to 
inhibit ATP synthase and mTOR signaling, further experiments were performed to analyze 
the proliferative capacity (Fu et al., 2015). 
 
Results were further confirmed by application of the CellTiter-Blue Assay, which is 
independent of ATP production, but dependent on NADP. However, results confirm that 
Idh1R132H also significantly decreases the colony formation rate (Figure 37 C). As the colony 
formation assay is a measure to examine the tumorigenic potential of cells, it points towards a 
missing capability of Idh1R132H alone to induce tumor formation. Mutant IDH1 produces high 
concentrations of the oncometabolite 2-HG, which amongst others modifies DNA and histone 
methylation and induces a block in differentiation (Dang et al., 2010; Ward et al., 2010). 
Based on this, one can assume that the suppressing effect observed shortly after induction of 
Idh1R132H is related to 2-HG. 
 
These results are in line with other studies describing a decreased proliferation rate due to 
mutant IDH1. Ectopic overexpression of IDH1R132H in glioblastoma cell lines leads to a 
reduced proliferation by downregulation of the Wnt/b-catenin signaling pathway (Cui et al., 
2016). Further results with comparable glioma cell line models were also reported in vitro and 
in an intracranial in vivo model (Bralten et al., 2011). On the other hand, there is also 
evidence that expression of Idh1R132H enhances proliferation. Expression of Idh1R132H in the 
mouse subventricular zone stem cell niche recapitulates features known for early 
gliomagenesis (Bardella et al., 2016). In this case it should not be disregarded that mutant 
cells were implanted in a neurogenic stem cell niche, which is a favorable environment and 
not comparable to an in vitro situation. Nevertheless, the present study shows that expression 
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of Idh1R132H could potentially induce proliferation. Furthermore, it points towards the 
importance of the surrounding environment. Unexpected was the finding of p53-/- leading to a 
significant decrease of cell viability (Figure 37 A). These results contrast the knock-out of 
Tp53 in human cancers, leading to a decrease in apoptosis and missing DNA repair, which 
enhances proliferation and accumulates further mutations (Brown and Wouters, 1999). 
 
The cells used in this study were treated with 4-OHT previously, inducing Cre recombination, 
which might have a growth-inhibitory effect. The 4-OHT treatment might be toxic, depending 
on time and dosage of 4-OHT (Loonstra et al., 2001). To avoid this, treatment of 4-OHT was 
tested in different concentrations before experiments started. It was clearly visible that a 
concentration of 1 µM 4-OHT did not have a growth suppressing effect, whereas cells died 
from tenfold higher concentrations (Supplement Figure 2). Further, control cells to p53-/- were 
also treated with 4-OHT and proliferation was not altered in these cells at all (Figure 37 A). 
Thus, it can be concluded that the decrease of cell viability due to induction of p53-/- is most 
probably a direct effect. As p53 is involved in several important cellular processes, such as 
cell cycle regulation and apoptosis, it might be that this has an impact on the cells’ behavior. 
p53 might for example alter ATP production, as colony formation was not affected in contrast 
to cell viability. The colony formation assay functions independent on ATP levels, but 
dependent on NADP+, which is also based on metabolism. Therefore, the colony formation 
assay should be carried out in 6-well format and colonies should be counted after staining 
with crystal violet. 
 
In line with the effects of either Idh1R132H or p53-/- alone, a combination of both did also 
decrease cell viability (Figure 37 A). Accordingly, the effect of mutant Idh1 with concomitant 
production of 2-HG cannot be rescued by an additional knock-out of Tp53. There is a 
tendency observable that double mutant cells have a growth advantage when compared to 
single Idh1R132H cells.  
 
In contrast to the effect of the Idh1R132H mutation on cell viability and colony formation, the 
decreasing effect of p53-/- and of the combination of both alterations was not observed in the 
CellTiter-Blue Assay (Figure 37 C). Experiments have rather shown that cells harboring the 
knock-out of Tp53 alone or in combination with mutant Idh1 are able to grow in an 
extracellular matrix-like environment, which is described as a hallmark of carcinogenesis in 
vitro. This might suggest that cells might be able to develop a tumorigenic behavior in vivo. 
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An interesting question here is whether p53-/- is immune to the effect of Idh1R132H on colony 
formation. To unravel this, cell viability should be measured in Tp53 knock-out cells treated 
with 2-HG. If 2-HG has no growth suppressing effect, this would confirm that p53-/- is 
immune to the Idh1 mutation with concomitant production of 2-HG. 
 
To further examine whether the reduced cell viability due to Idh1R132H might be mimicked by 
an enhanced rate of apoptosis, Western blot experiments were performed. For this 
experiment, late apoptotic proteins were chosen for analysis, as they only affect the very 
downstream part of the signaling cascade. Caspase 3 and 7 are also called executioner 
caspases, irreversibly inducing apoptosis without another contributor (Fuchs and Steller, 
2011). Results have shown that there was no significant effect of Idh1R132H on apoptosis, 
further evidencing that the proliferative capacity is decreased (Figure 37 E). This is in contrast 
to the enhanced levels of apoptosis associated with IDH1R132H (Cui et al., 2016). The 
explanation for this opposing result might be based on a different model system. Human 
glioblastoma cell lines were used with an overexpression of IDH1R132H, which is a different 
background. Glioblastomas are tumors that do not per se carry the IDH1R132H mutation, which 
might explain the different behavior.  
 
A knock-out of Tp53 either alone or in combination with Idh1R132H shows a tendency of 
decreased apoptotic levels (Figure 37 E). Protein 53 is thought to induce apoptosis by 
transcriptional activation of Bax, Noxa and PUMA, which subsequently stimulate the release 
of Diablo/Smac and also cytochrome c from mitochondria. These meanwhile inhibit specific 
inhibitors of apoptosis proteins and finally activate caspases (Schuler and Green, 2001). Thus, 
the tendency towards decreased levels of clC 3, clC 7 and clPARP could be explained by a 
reduced p53 induced apoptotic signaling due to the knock-out. As it can also be inferred from 
the figure, small effects can only hardly be observed due to a high variance between replicas. 
This variance might be due to detection of very small proteins with Western blot, but also 
because of cellular changes influencing apoptosis. Although experiments were performed 
consecutively, it took three weeks to collect lysate from three biological replicas. If the 
induction of genetic alterations might have impacted apoptosis in this period, this could lead 
to a higher variance seen in Western blot results. To exclude technical problems, experiments 
should be carried out examining rates of apoptosis, which are not based on protein. As a first 
attempt, a new assay was applied allowing real-time monitoring of apoptosis with a 
luminescent readout, which did not work reliably.  
Discussion 
 
	80	
The experiments carried out after induction of Idh1R132H with or without a knock-out of Tp53 
have shown that induction of Idh1R132H has a growth suppressing function (Figure 37). The 
effects are most probably due to the high amounts of 2-HG produced and indicate that these 
cells are not able to induce tumorigenesis.  
 
4.2 The difference between short- and long-term inductions 
Long term cultivation of the cells leads to a different phenotype compared to short-term 
cultures. The proliferative capacity of cells harboring both Idh1R132H mutation and a knock-out 
of Tp53 is significantly enhanced compared to single mutants (Figure 37 B). 
Immunohistochemistry with antibodies to cell cycle markers additionally revealed that more 
cells with both alterations are proliferating. This growth advantage observed in double 
mutants compared to single mutants points towards a cooperative effect of p53-/- in an 
Idh1R132H background. This was further confirmed with the soft agar assay, showing that 
double mutants formed about three times more colonies compared to single mutants (Figure 
37 D). The data indicate that a development towards a more tumorigenic phenotype took 
place across time, as the potential to grow in an extracellular matrix-like environment is 
described as a hallmark of carcinogenesis in vitro. Proliferative behavior did only change in 
cells with a combination of the genetic alterations and not in single mutants, which proposes 
the question about the difference between the occurrence of the mutations alone and in 
combination. The increase of the colony formation rate in double mutants was not significant, 
but there was a strong tendency towards enhanced formation. This could be explained by a 
large variance between biological and technical replicates, which might be due to for example 
different charges of the soft agar prepared. As already explained one should consider 
conducting the assay in a greater format and count the colonies after crystal violet staining. 
 
DNA methylation was analyzed with Dotblot experiments, showing that the presence of 
mutant Idh1 did not significantly alter 5mC and 5hmC levels. However, Idh1R132H expressed 
alone, revealed a tendency towards increased levels of both markers. This tendency was not 
observable in cell lines harboring the knock-out of Tp53 only. These experiments indicate that 
DNA methylation was not altered after presence of the genetic alterations for several months.  
Given the fact that mutant IDH1 has effects on epigenetics through the inhibition of α-KG 
dependent enzymes, it should be taken into account to perform further experiments to analyze 
hydroxymethylation. Although the dotblot method could be used to analyze the samples, the 
variance was high between technical replicates, which might be due to sample normalization. 
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Normalization was performed on the methylene blue control staining on each spotted DNA 
dot, which strongly depends on the brightness of the picture. As a different method to 
quantify abundance of 5mC and 5hmC one might perform mass spectrometry, which is a very 
sensitive method. With this approach, the different intermediate stages (such as 5-
formylcytosine) between 5mC and 5hmC can also be quantified.   
 
As for short-term cells, apoptosis was also examined in more detail in cells with alterations 
present for a period of more than six months. Idh1R132H p53-/- cells showed an enhanced 
expression signal for all apoptotic proteins tested (Figure 37 F). This result was in strong 
contrast to the decreased level of apoptosis measured in cells with one alteration only. On the 
one hand, this result is in line with previous experiments indicating that double mutants 
behave in an opposite way compared to single mutants, which was not seen shortly after 
induction. This increase might suggest that cell numbers measured in the cell viability assay 
should be even higher, which is hidden by enhanced apoptosis. On the other hand, an 
enhanced rate of apoptosis is to be against the observation that cells have an increased 
proliferative capacity. A knock-out of Tp53 should lead to decreased levels of apoptosis 
because of the missing p53-induced signal initiating apoptotic pathways. A possible 
explanation for this might be that other members of the p53-family might have induced 
apoptotic pathways. In a drosophila model cells do have caspase-dependent but p53-
independent pathways of apoptosis induced via other proteins of the p53 family, such as p73 
(Wichmann et al., 2006). It was described that the transcription factor E2F-1, inducing the 
transcription of p73, induces apoptosis in p53-defective tumor cells and p53-/- mouse embryo 
fibroblasts (Irwin et al., 2000). In line with the results about enhanced apoptosis but also 
proliferation, expression of p73 is increased in some human cancers, as for example in glioma 
(Pietsch et al., 2008). Thus, the results on apoptosis might be explained by other proteins 
involved in signaling cascades of cell death. 
 
Another different approach to explain enhanced levels of apoptosis would be the model itself, 
in other words the formation of spheres. As sphere formation and proliferation takes place 
faster in these cultures, the core of spheres gets apoptotic faster as well. The core of the 
spheres gets hypoxic as nutrients cannot reach all cells, which leads to apoptosis (Edmondson 
et al., 2014). Additionally, larger spheres also have more apoptotic cells, which are still 
present in the lysate used for Western blot analysis. From a technical point of view, this might 
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also explain an increase of apoptosis in double mutant cells with an enhanced proliferative 
capacity.  
 
The results further challenge why the double mutants behave in a different way compared to 
single mutants. It is known that loss of p53 induces chromosomal instability, which might 
point towards the occurrence of unknown other mutations. The accumulation of additional 
mutations could further support cell viability and proliferation, which was also observed. 
Interestingly, one mutation alone was not sufficient to induce this phenotype, suggesting that 
the possible chromosomal instability induced by Idh1R132H and p53-/- led to the accumulation 
of additional mutations. To further investigate this, sequencing analysis of exactly these long-
term cultures should be performed in order to check for possible other mutations. Recent 
evidence suggests that mutant IDH1 affects DNA repair enzymes thereby favoring induction 
of genome instability and accumulation of additional mutations (Chen et al., 2017a). In line 
with this, Idh1R132H alone induces genome instability in cells as well, but it remains to be 
investigated, why p53 is needed to induce enhanced cell viability and proliferation.  
 
Another interesting aspect is that cells harboring one mutation only do not have normal levels 
of apoptosis but rather decreased levels (Figure 37 F). In case of the knock-out of Tp53 alone, 
this could be explained by a reduction of apoptosis initiated by the knock-out. However, 
Idh1R132H cells obviously also have a reduction accompanied by a decrease of proliferation. 
This observation might be explained by the slowly growing behavior of the cells, which 
means that there is only a small number of apoptotic cells present per sphere. 
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Figure 37. Summary of the functional analysis of the established cell lines at different 
time points. A Cell viability is significantly decreased in Idh1R132H mutated cells as well as 
p53-/- cells and double mutants. B The growth disadvantage of single mutant cells in short-
term cultures cannot be observed in long-term cultures. A combination of Idh1R132H and p53-/- 
significantly increases cell viability six months after initial induction. C Idh1R132H 
significantly decreases colony formation rate, whereas no effect can be observed in p53-/- cells 
and double mutants. D The reducing effect of Idh1R132H on colony formation can still be 
Short-term Long-term 
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observed after long-term cultivation. Idh1R132H in combination with p53-/- shows a tendency to 
build more colonies in soft agar. E Abundance of late apoptotic proteins is not significantly 
altered after induction of the genetic alterations. F Cultivation across six months leads to a 
significant increase of apoptotic rates in double mutant cells, but not in single mutants.  
G Induction of Idh1R132H leads to a high production of 2-HG, also in combination with p53-/-. 
H Production of 2-HG cannot be measured in all long-term cultures, independent of the initial 
induction of Idh1R132H. 
 
4.3 Loss of Idh1R132H in vitro 
Genotyping revealed that Idh1R132H was lost in all long-term cultures, but it appeared always 
in a different manner. As a next step, it would be crucial to investigate this loss in more detail 
and compare the result of different cultures. Whole-genome bisulfite sequencing of the 
different cell lines could unravel whether the breaking points at the borders of the loss have 
different features in addition to methylation patterns. One of the challenges in this regard is 
the missing specificity of mouse libraries, strongly depending on the genetic background. The 
differences of the libraries make it difficult to discriminate between genome and mutations. In 
other words, it is difficult to detect the true mutations. To avoid these problems, it would be 
crucial to prepare an own reference genome dependent on the mice strain worked with. 
 
In this context first attempts were undertaken to investigate what actually initiated the genetic 
aberration. Genome instability is defined as an increase of genome required mutations. The 
mechanisms leading to genome instability include defects in the DNA damage response or 
more often in DNA double-strand breaks repair (Georgoulis et al., 2017). To investigate 
whether double-strand breaks might be the reason for genome instability and the concomitant 
loss of the Idh1R132H mutation, Western blot experiments should be performed to check for the 
level of γH2AX. When double-strand breaks are generated into DNA, γ-phosphorylation 
takes place at serine 139 of the histone H2AX, which can be visualized with specific 
antibodies (Kuo and Yang, 2008). A first experiment has indicated that newly induced cells 
might have enhanced expression levels of γH2AX protein (Supplement Figure 3). 
Experiments need to be repeated with lysates prepared in SDS buffer to improve blot results. 
Due to the difficulties with Western blot experiments, one might also conduct cytospins of the 
cells to perform immunofluorescent stainings on these slices to detect γH2AX expression. As 
another approach, it might also be possible to carry out a Comet assay, which has not been 
established so far.  
 
Discussion 
 
	 85	
A further interesting question is the time of initiation of these events. To answer this question, 
cell lines induced from different time points should be checked for genome instability and 
compared. Based on the results that mutant Idh1 is completely lost in a whole culture after 
one to two months suggests that it might be an event that takes place early after induction.  
 
If the initiation of the IDH1R132H mutation is associated with the induction of genome 
instability, it might be conceivable that the production of 2-HG is responsible for this. 
Experiments should be conducted with newly induced cells and the respective controls and 
treated with an inhibitor against IDH1R132H, diminishing the production of 2-HG. If there 
would be no evidence for genome instability in the induced cell lines after inhibitor treatment, 
the effect could most probably be ascribed to 2-HG.  
 
Murine NSCs harboring an Idh1R132H mutation lose the mutation in vitro, which could also be 
observed when cultivating human glioma derived cells (Pusch, 2017). It would be very 
interesting to compare the loss of mutant IDH1 between the different human cultures and the 
properties of the original tumor. The question should be answered whether there is a 
correlation between human and murine derived cultures. 
 
Regarding the comparison between human and murine system, it should be investigated why 
cells obviously do not lose the Idh1R132H mutation in vivo.  
 
4.4 Migration of induced NSCs in vivo 
Intracranial injection of the induced NSCs was successful and cells started to invade the brain, 
which was observed two months after implantations. Monthly MRI screens showed a lesion in 
the area of implantation eight months after injection. A lesion could be observed in one mouse 
implanted with p53-/- cells and in two mice with Idh1R132H p53-/- cells. A progression of tumor 
growth could not be achieved in Idh1R132H p53-/- mice and a lesion could only barely be 
detected two months later. It could be questioned whether the length of the experiment was 
chosen correctly (Figure 38). The decrease of the lesion volume during the course of the 
experiment suggests that it should be terminated at eight months for detailed analysis of the 
observed lesions. However, the experiment was carried out twelve months as planned and 
histological analysis was performed afterwards. These stainings indicate that a solid tumor 
was not observable twelve months after surgery and that the implanted cells started to migrate 
across the corpus callosum to different lateral brain areas. 
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Another interesting observation is that the mouse implanted with p53-/- cells first showed a 
decrease of the tumor volume at the ninths months, but than a progression from months ten 
onwards. This finding is in contrast to mice injected with double mutant NSCs. A possible 
explanation might be that the p53-/- cells accumulated further mutations promoting 
tumorigenesis, which did not happen in double mutants. 
 
 
Figure 38. Timeline of the in vivo study. Implanted NSCs started to invade the brain tissue 
after intracranial injection. Tumor outgrowth was observed in mice implanted with IDH1R132H 
p53-/- cells after eight months. After eight months, tumors disappeared in MRI images due to 
migration of the implanted NSCs observed after termination of the experiment.   
 
4.5 Cell type 
Studies have identified tumorigenic, stem-cell like precursor cells in advanced stage gliomas, 
suggesting a neural stem cell origin (Noushmehr et al., 2010; Turcan et al., 2012). These 
findings are not in line with the results described here, indicating that it might be another cell 
type involved in the initiation of gliomagenesis. The injected NSCs migrated to different brain 
areas and did not form a solid tumor. It might be a further differentiated cell type such as 
astrocytes for example that is able to induce tumor formation if genetically altered. In this 
context, the mutated NSCs should be further differentiated in culture before intracranial 
injection.  
 
It was observable that the presence of the genetic alterations across a period of more than six 
months altered the behavior towards a more tumorigenic phenotype. Thus, it would be 
interesting to know whether these cells behave differently in an in vivo environment, 
compared to the newly induced cells that were actually implanted. However, disregarding the 
proliferative advantage of these cells in vitro, it was shown that the Idh1R132H mutation was 
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not present anymore. This is definitely an issue that would discriminate this system from the 
human one. Independent on the hypothesis that IDH1R132H is believed to be a driver mutation, 
human gliomas do only very rarely lose the mutation. Given that the aim was to build an in 
vivo allograft model that mimics the features of human gliomagenesis, it would be reasonable 
to next implant the genetically altered NSCs in another differentiation stage. 
 
4.6 Additional mutation 
In addition to the cell of origin that is able to induce tumorigenesis, another important aspect 
is certainly the combination of mutations. In the present study, Idh1R132H was tested as a 
possible initiating mutation and combined with a knock-out of Tp53 to mimic the genetic 
features of astrocytoma, or with a knock-out of Cic trying to mimic oligodendroglioma. Other 
alterations are known to occur mutually exclusive from others and are specific for tumor 
entities. Conceivably, further or at least a third alteration might be needed to induce 
gliomagenesis. As a third alteration specific for astrocytoma, the knock-down of Atrx should 
be implemented. In the long run, triple mutant cells harboring the Idh1R132H mutation, a 
knock-out of Tp53 and a knock-down of Atrx cells should be analyzed in vitro and later be 
injected intracranially. 
 
4.7 Genetic background of mice 
To further improve the model system, the mouse strain worked with is an important issue to 
discuss. Working with immunodeficient BALB/c nude mice on a long term was very difficult 
with respect to unexpected diseases, such as infections. These incidences as well as major 
problems experienced with injection anesthesia during surgeries reduced the mouse number 
per group during the course of the study for reasons not related to the initial question. 
Additionally, the study was aimed at observing possible tumor outgrowth on a long run, 
which needs stable conditions. It was reported that the adaptive immune response, normally 
absent in BALB/c mice, tends to return. This important change might have influenced the 
beginning tumor formation observed in MRI recordings after eight months. If the immune 
response started to increase during this time, it might have altered tumor growth and thus, did 
finally lead to a reduction of tumor volume. This observation was made in the upcoming 
months until lesions could not be detected anymore. These results suggest that re-implantation 
should be performed in a different immunodeficient mouse strain, as for example Rag2.  
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Concerning the presence of the immune system, it would be of high importance to also 
investigate the effects of implantations of NSCs with production of 2-HG in an immune 
background. In this context, different scenarios are imaginable. Studies have shown that 2-HG 
causes down-regulation of leukocyte chemotaxis, which leads to suppression of the tumor-
associated immune system by decreasing tumor cell infiltration (Amankulor et al., 2017). 2-
HG decreases the production of the T cell-attracting chemokines CXCL 9 and 10 as well as its 
regulator STAT1, which in turn inhibits migration of T cells towards the tumor (Kohanbash et 
al., 2017). This might explain why IDH1 mutated tumors behave less aggressive and 
infiltration of immune cells is linked to a poor prognosis in patients. Thus, it might be 
possible that the effect of Idh1R132H is suppressive in immunocompetent mice and 
tumorigenesis is inhibited irrespective of the initial presence of the immune system. In 
contrast, as Idh mutations influence genome instability and most probably induce the 
accumulation of additional mutations, it might be feasible that selection of a more aggressive 
phenotype takes place. This in turn might be enough to initiate tumorigenesis even in an 
immunocompetent background. 
 
4.8 Detection of implanted cells 
Two months after implantation, Idh1R132H positive cells surrounding the injection puncture 
invaded the brain parenchyma. This is in contrast to mice that lived until termination of the 
experiment, where no Idh1R132H positive cells could be detected in the initial area of 
implantation but in different lateral brain areas. Application of the mouse Idh1R132H antibody 
on murine tissue has some disadvantages, such as the high background signal due to the 
mouse secondary antibody used. However, careful analysis of the slices indicates that 
Idh1R132H p53-/- cells in the lateral brain areas showed a light brownish cytoplasmic granular 
staining whereas the nucleus was clearly omitted. Staining against Idh1R132H gives only 
information about the induced cells and does not prove existence of non-inducible control 
cells. But application of different antibodies, such as Foxn1, did not deliver reliable results. 
Taken together, detection of the injected cells after termination of the experiment seems to be 
challenging, making it inevitable to think about different detection methods for future 
experiments.  
 
First, it could be an option to label cells prior to injection, with a fluorescent protein such as 
GFP. However, the insertion of GFP is questionable due to its immunogenicity when used in 
an immunocompetent background (Ansari et al., 2016). Another option would be to 
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implement dyes, which are not immunogenic. It should be taken into account that the 
establishment of an in vivo glioma model is always accompanied by a long observation period 
and dyes might not be kept in the cells on a long run. One possible scenario would be to 
implement a fluorescent protein in mice prior to final matings for stem cell preparation. The 
already existing mice harboring the conditional alleles might be crossed with e.g. a mCherry 
mouse, also with a Bl6N background. After preparation of NSCs from these mice, injections 
could be performed into Bl6N tomato mice, making it finally possible to discriminate between 
the differentially labeled cells. 
 
Second, a completely different approach would be to make use of the production of 2-HG 
from injected cells harboring the Idh1R132H cells. Preliminary experiments have already been 
performed at the University Clinics Heidelberg, trying to map the release of 2-HG from 
glioma cells with 9.4 T MRI scans (Neuberger, 2017). However, it is questionable, whether 
the given resolution is sufficient to clearly detect the cells by using this approach. This option 
would not solve the problem of detecting any type of injected cell, independent of the 
mutational status. 
 
Third, one method to validate protein expression with immunohistochemistry is the analysis 
of RNA levels with RNAscope in situ hybridization. RNAscope provides a higher resolution 
signal at cellular level and probes are available to detect Cre recombinase as the protein of 
interest. Some additional devices are needed for these experiments, which are not yet 
established in the lab. 
 
Fourth, yet another possibility is the detection of 2-HG with Matrix Assisted Laser Desorption 
Ionization - Time of Flight (MALDI-TOF). This method was recently published to be suitable 
for the detection of 2-HG in brain tumor slices with a resolution of 50 µm (Giampa et al., 
2016; Longuespee et al., 2018). This resolution might be too weak for the detection of single 
cells, making it inevitable to use another device with a better resolution. 
 
4.9 Implementation of Cic-/-  in an Idh1R132H background 
Cells harboring a knock-out of Cic in an Idh1R132H background were generated and analyzed 
in vitro but also in vivo by intracranial injection into immunodeficient mice. CIC was 
described to have a key role in regulating growth by the RTK/Ras pathway and cell fate 
determination, which does vary between tissues (Tseng et al., 2007). The result that Cic-/- cells 
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show enhanced cell viability is in line with studies describing that CIC acts as a tumor 
suppressor gene by repressing downstream targets of RAS/MAPK signals. In brain tumors, 
CIC mutations are specific to oligodendroglioma and are frequently associated with IDH1 and 
FUBP1 mutations, questioning its cooperativity (Jiao et al., 2012). Implementing the 
Idh1R132H mutation and Cic-/- showed that cell viability as well as colony formation in soft 
agar was not altered. Cultivation of these double mutant cells across a long term has shown 
that overall proliferation was much slower compared to other NSCs with different genetic 
alterations. This observation is also in line with another study reporting that mutations in CIC 
and IDH1 negatively affect cell clonogenicity by affecting the cytosolic citrate metabolism 
(Chittaranjan et al., 2014). Combination of the IDH1 and CIC mutation increased levels of 2-
HG compared to wild-type CIC in an IDH1R132H background. In the present study, there was 
only a tendency of enhanced levels of 2-HG, but the calculated mean did not significantly 
differ between single Idh1R132H cells and double mutants. This difference between 
experiments might be based on differences in the model systems. Another significant 
observation was that double mutant cells did not lose the Idh1R132H mutation if it was 
accompanied by Cic-/-. This result is in contrast to cells harboring the Idh1R132H mutation 
either alone, or together with a knock-out of Tp53. Mutant Idh1 is accompanied by a 
significant growth disadvantage, as long as the mutation is present in the cells, which might 
explain why Idh1R132H Cic-/- cells tend to grow slower. The repressing effect of Idh1R132H Cic-/- 
on proliferation also fits the common growth behavior of oligodendroglioma, which does 
proliferate slower compared to astrocytoma for example. The slowly growing phenotype 
observed in vitro might also explain why no lesion could be detected in MRI screens. Missing 
formation of a solid tumor might also be due to recurring of the immune system in BALB/c 
nude mice inhibiting beginning tumorigenesis. 
 
The Cic knock-out does not alter the phenotype of Idh1R132H regarding cell viability and 
proliferation, DNA methylation and production of 2-HG. These results allow the hypothesis 
that the Cic knock-out alone does not mimic the complete 1p/19q loss of heterozygosity, 
which might require additional genetic alterations. An additional genetic alteration is the 
mutation of the telomerase reverse transcriptase promoter (pTERT). These mutations occur in 
about 90% of gliomas with 1p/19q co-deletions. CIC mutations are associated with pTERT 
mutations in 85% of oligodendrogliomas with 1p/19q LOH (Labussiere et al., 2014). 
Telomere maintenance mechanisms, such as pTERT mutations in oligodendroglioma, or 
ATRX mutations in astrocytoma, is described in more than 80% of gliomas and thus seems to 
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be a unique feature of these tumor entities. The close correlation of IDH1R132H, with CIC and 
pTERT alterations known as the molecular signature of oligodendroglioma, would definitely 
improve the model system described here. It remains to be seen whether an additional pTERT 
mutation affects the Idh1R132H phenotype described here. 
 
4.10 Functional neuroimaging of glioma xenografts with IDH1R132H mutation 
To investigate the association between IDH1R132H and epileptogenesis, functional 
neuroimaging was performed with FDG PET. PET results showed that there is no indication 
of hypometabolism in the left hemisphere of mice harboring a glioma with IDH1R132H 
mutation in the right hemisphere. There is no difference in glucose metabolism between all 
experimental groups (Figure 35). Furthermore, BALB/c nude mice behave in a different way 
as expected, as accumulation of FDG was only barely observed in the brain. This points 
towards a general problem of the mouse strain used for PET recordings. For future 
experiments, it should be taken into account to use immunodeficient mice with fur. The 
strongly enhanced regions of glucose metabolism in regions of the thorax in BALB/c nudes 
might be associated with prevention to lose warmth during PET recordings and anesthesia. 
This problem is not known for fur mice and might thus help to perform PET imaging with 
normal uptake of FDG.  
 
Pretreatment with an IDH1R132H specific inhibitor before PET recordings does not 
significantly alter FDG distribution between groups. No clear evidence of seizure activity can 
be detected. These data suggest that the given parameters are most probably not sufficient to 
clearly detect seizures in mice. However, there was a tendency of an increase in activity after 
treatment with BAY1436032 in the group harboring a glioma with IDH1R132H mutation. This 
might point towards a state of hypometabolism prior to inhibitor treatment, possibly because 
of epileptogenesis in these mice. Here, it would be an advantage to also image a mouse from 
an epileptic animal model to finally investigate whether seizure activity can be observed with 
the given methods and compare it to the data obtained. 
 
It is still a matter of debate whether FDG can be used as a reliable radiotracer for the detection 
of seizures. It was reported that glucose hypometabolism monitored with FDG PET does not 
precisely correlate with, for example, the alteration within hippocampal sclerosis responsible 
for epileptogenesis observed by MRI. It was suggested that for example Benzodiazepine-
receptor imaging might be a promising alternative to image the epileptogenic zone. 
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Concerning different radiotracers, 18F-flumazenil (FMZ) was described to be a tracer of 
choice in patients suffering from refractory epilepsy, because of a better sensitivity and 
anatomical resolution (Hodolic et al., 2016). Independent of the precision of different tracers, 
it seems to be a general problem that different tracers are more or less suitable for different 
types of seizures, which should be taken into account in further studies.  
 
Due to this issue, for further in vivo studies targeting the question of the concomitant 
occurrence of IDH1R132H mutated glioma and epileptogenesis, more invasive approaches 
might be used. Intracranial EEG with electrodes located in the area surrounding the tumor 
would reveal whether ictal high frequency oscillations can be observed as an indication for 
seizures. But also in this case it would be very interesting to examine whether IDH1R132H and 
the treatment with BAY1436032 affect seizure occurrence. As this inhibitor is also being used 
in patients, it would be important to investigate this aspect. 
 
In vitro, it would additionally be interesting to investigate the direct effect of 2-HG on 
intrinsic brain activity. With slice cultures and electrophysiological methods, such as field 
recordings, it could be observed whether treatment with exogenous 2-HG does affect levels of 
excitation and inhibition. The experimental settings are however not that trivial as 2-HG only 
barely enters cells. Another aspect to analyze in vitro would be to look in slice cultures from 
glioma bearing mice whether activity in the area surrounding the tumor differs between mice 
with an IDH1R132H mutated glioma and those that lack this mutation. This would not only give 
an indication for an alteration of normal brain activity, but application of epileptic drugs 
might directly confirm whether this activity can be blocked.  
 
In addition to in vivo and in vitro analysis, it might also be investigated with 
immunohistochemistry and the application of different antibodies, whether there are 
differences between different groups of mice. A recent publication has shown that high 
expression of cysteine-glutamate antiporter xCT (SLC7A11) serves as a biomarker for initial 
occurrence of seizures in patients with glioma (Sorensen et al., 2018). However, this finding 
was not associated with the presence of IDH1R132H. Nevertheless, it shows that biomarkers 
investigated with immunohistochemistry might help to detect epilepsy in brain slices as well. 
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5 Summary 
 
The aim of this project was to develop a mouse allograft model based on neural stem cells 
displaying the key properties of human glioma on the molecular level. Therefore, neural stem 
cells were prepared from mice harboring different genetic features of astrocytoma or 
oligodendroglioma. Common to both are mutations of isocitrate dehydrogenase. A specific 
type of mutation leads to production of D-2-hydroxyglutarate, a known oncometabolite, 
which is thought to be essential for tumor initiation. The accumulation of D-2-
hydroxyglutarate leads to epigenetic reprogramming and thereby to tumor formation. 
 
Neural stem cells with inducible isocitrate dehydrogenase R132H knock-in and inducible 
Tp53 knock-out were analyzed for their tumorigenic potential with different assays. None of 
the manipulations or combinations thereof showed an enhanced tumorigenic potential. While 
in cells with isocitrate dehydrogenase mutation R132H cell growth was compromised by D-2-
hydroxyglutarate production, this was not observed in combination with the loss of p53. To 
analyze if these cells show a different tumorigenic potential in vivo, they were injected 
intracranially into immunodeficient mice. Potential tumor outgrowth was monitored with 
regular MRI screens and was evident after eight months. It was reasonable to keep the cells in 
culture for a longer time, because epigenetic reprogramming can take several passages to 
manifest. Those “long-term” cultures grew more aggressively compared to their recently 
induced (“short-term”) counterparts. This could mainly be explained by the loss of the 
isocitrate dehydrogenase mutation, which is a negative selection marker under in vitro 
conditions. Such a phenomenon is already described in human cell lines. In contrast to the in 
vitro situation, the isocitrate dehydrogenase mutation was kept in vivo, although the tumors 
disappeared within twelve months. 
 
In conclusion, the project could show that the combination of isocitrate dehydrogenase 
mutation R132H together with the loss of p53 is beneficial for the cells and sufficient to 
initiate tumor formation. The model nicely pictures the human system, in which cells in 
culture lose the mutation, but tumors only rarely do. It is perfectly suited for the investigation 
of the essential function of isocitrate dehydrogenase mutation in glioma. By this it will help to 
understand this function, uncover weaknesses of these tumors and help to predict resistance 
mechanisms against isocitrate dehydrogenase mutation inhibitors. Further development of the 
system by addition of other genetic alterations will potentially lead to more durable tumors in 
vivo.  
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6 Zusammenfassung 
 
Ziel des Projekts war die Entwicklung eines murinen Gliom Modells. Dieses auf neuralen 
Stammzellen basierende Modell, sollte die molekularen Veränderungen von humanen 
Gliomen aufweisen und in der Maus zu einem Tumor führen. Um dieses Ziel zu erreichen 
wurden neurale Stammzellen aus Mäusen gewonnen, welche die genetischen Eigenschaften 
von Astrozytomen und Oligodendrogliomen haben. Eine Gemeinsamkeit von beiden Entitäten 
ist die Mutation des Enzyms Isocitrat-Dehydrogenase. Eine bestimmte Mutation dieses 
Enzyms führt zu der Produktion des Onkometaboliten D-2-Hydroxyglutarat. Man vermutet, 
dass dies ein essentieller Schritt in der Tumorentstehung ist, weil die Anreicherung von D-2-
Hydroxyglutarat zur epigenetischen Umprogrammierung führt und damit die 
Tumorentstehung fördert. 
 
Das tumorigene Potential von neuralen Stammzellen mit einer induzierbaren Isocitrat-
Dehydrogenase R132H Knock-in Mutation und einem induzierbaren Tp53 Knock-out wurde 
mit verschiedenen Methoden untersucht. Keine Kombination der genetischen Veränderungen 
zeigte ein erhöhtes tumorigenes Potential. Die spezifische Isocitrat-Dehydrogenase R132H 
Mutation zusammen mit einem Verlust von p53weist nicht die reduzierte Zellvitalität auf, wie 
sie in Zellen mit nur der Isocitrat-Dehydrogenase Mutation beobachtet wurde. Um zu 
analysieren, ob die Zellen in vivo ein anderes tumorigenes Verhalten zeigen, wurden die 
Zellen intrakranial implantiert. Tumorwachstum wurde mit regelmäßigen MRT 
Untersuchungen kontrolliert und konnte nach acht Monaten beobachtet werden. Da 
epigenetische Veränderungen erst nach mehreren Passagen sichtbar werden, wurden die 
Zellen für eine längere Zeit kultiviert. Diese Langzeitkulturen zeigten wesentliche 
Unterschiede zu ihren genetisch vergleichbaren frisch induzierten Zellen. Dieses Verhalten 
kann durch den Verlust der Isocitrat-Dehydrogenase Mutation erklärt werden, die ein 
negativer Selektionsmarker unter in vitro-Bedingungen ist. Ein solches Phänomen wurde 
schon für humane Zelllinien beschrieben. Im Gegensatz zu der in vitro-Situation blieb die 
Isocitrat-Dehydrogenase Mutation in vivo erhalten, auch wenn die Tumore innerhalb von 
zwölf Monaten wieder verschwunden waren.  
 
Zusammenfassend konnte dieses Projekt zeigen, dass die Kombination aus der Isocitrat-
Dehydrogenase R132H Mutation gemeinsam mit dem Verlust von p53 vorteilhaft für Zellen 
ist und ausreicht, um Tumorwachstum zu initiieren. Dieses Modell spiegelt sehr gut das 
humane System wieder, bei dem auch Zellen in Kultur die Mutation verlieren, was hingegen 
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nicht in Tumoren zu beobachten ist. Des Weiteren ist es sehr gut geeignet, um die essentiellen 
Funktionen der Isocitrat-Dehydrogenase Mutation in Gliomen zu untersuchen. Dies würde 
helfen, die Funktion zu verstehen, die Schwachstellen dieser Tumore aufzudecken und dazu 
beitragen, Resistenzmechanismen gegen spezifische Inhibitoren der Isocitrat-Dehydrogenase 
Mutation zu finden. Die Weiterentwicklung dieses Systems, zum Beispiel durch das 
Einbinden weiterer genetischer Veränderungen, hat das Potential, zu stabilerem 
Tumorwachstum in vivo zu führen. 
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8 Supplement 
 
Supplement Table 1. All established neural stem cell cultures with the dates of preparation 
and respective genotypes. C, conditional allele; T, transgenic allele. 
Date of 
preparation 
Cell culture 
number 
Idh1R132H 
genotype 
ROSA-
CreERT2 
genotype 
p53 genotype Cic genotype 
12.01.2015 #1 C/+ T/+ - - 
12.01.2015 #2 C/+ +/+ - - 
12.01.2015 #3 C/+ T/+ - - 
12.01.2015 #4 C/+ T/+ - - 
12.01.2015 #5 C/+ T/+ - - 
12.01.2015 #6 C/+ T/+ - - 
12.01.2015 #7 C/+ T/+ - - 
12.01.2015 #8 C/+ T/+ - - 
12.01.2015 #9 C/+ +/+ - - 
12.01.2015 #10 C/+ T/+ - - 
15.01.2015 #11 C/+ T/+ - - 
15.01.2015 #12 C/+ +/+ - - 
15.01.2015 #13 C/+ T/+ - - 
15.01.2015 #14 C/+ T/+ - - 
15.01.2015 #15 C/+ +/+ - - 
15.01.2015 #16 C/+ +/+ - - 
15.01.2015 #17 C/+ T/+ - - 
18.08.2015 #18 C/+ T/+ C/C - 
18.08.2015 #19 +/+ T/+ C/C - 
18.08.2015 #20 +/+ T/+ C/C - 
18.08.2015 #21 C/+ T/+ C/C - 
18.08.2015 #22 +/+ T/+ C/C - 
18.08.2015 #23 C/+ T/+ C/C - 
18.08.2015 #24 +/+ T/+ C/C - 
18.08.2015 #25 C/+ T/+ C/C - 
14.10.2015 #26 C/+ +/+ C/C - 
14.10.2015 #27 +/+ +/+ C/C - 
14.10.2015 #28 C/+ +/+ C/C - 
14.10.2015 #29 +/+ T/+ C/C - 
14.10.2015 #30 C/+ +/+ C/C - 
14.10.2015 #31 C/C T/+ C/C - 
14.10.2015 #32 +/+ +/+ - +/+ 
14.10.2015 #33 +/+ +/+ - C/+ 
14.10.2015 #34 +/+ T/+ - +/+ 
14.10.2015 #35 +/+ +/+ - C/+ 
14.10.2015 #36 +/+ T/T - C/+ 
14.10.2015 #37 +/+ +/+ - C/+ 
14.10.2015 #38 +/+ T/T - C/+ 
14.10.2015 #39 +/+ +/+ - C/+ 
14.10.2015 #40 +/+ T/+ - C/+ 
08.12.2015 #41 +/+ T/+ - C/C 
08.12.2015 #42 +/+ T/+ - C/C 
08.12.2015 #43 +/+ T/+ - C/+ 
08.12.2015 #44 +/+ +/+ - C/C 
08.12.2015 #45 +/+ T/+ - C/C 
08.12.2015 #46 +/+ +/+ - C/+ 
08.12.2015 #47 +/+ +/+ - C/+ 
10.12.2015 #48 +/+ +/+ - C/+ 
10.12.2015 #49 +/+ T/+ - C/C 
10.12.2015 #50 +/+ +/+ - C/+ 
10.12.2015 #51 +/+ +/+ - C/C 
10.12.2015 #52 +/+ T/+ - C/C 
10.12.2015 #53 +/+ +/+ - C/C 
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10.12.2015 #54 +/+ +/+ - C/+ 
20.05.2016 #55 +/+ T/+ - C/+ 
20.05.2016 #56 +/+ T/+ - C/C 
20.05.2016 #57 C/+ T/+ - C/C 
20.05.2016 #58 +/+ T/+ - C/C 
20.05.2016 #59 C/+ +/+ - C/C 
20.05.2016 #60 +/+ T/+ - C/C 
24.05.2016 #61 C/+ T/+ - C/+ 
24.05.2016 #62 +/+ +/+ - C/C 
24.05.2016 #63 +/+ T/+ - C/+ 
24.05.2016 #64 C/+ +/+ - C/C 
24.05.2016 #65 +/+ T/+ - C/+ 
24.05.2016 #66 C/+ +/+ - C/+ 
24.05.2016 #67 +/+ T/+ - C/C 
31.05.2016 #68 C/+ +/+ - C/+ 
31.05.2016 #69 +/+ T/+ - C/+ 
31.05.2016 #70 +/+ +/+ - C/C 
31.05.2016 #71 C/+ T/+ - C/C 
31.05.2016 #72 +/+ T/T - C/C 
31.05.2016 #73 +/+ T/T - C/C 
31.05.2016 #74 +/+ T/+ - C/C 
31.05.2016 #75 C/+ T/+ - C/C 
 
 
Supplement Table 2. List of primers with respective sequences and annealing temperatures 
for PCR analysis. 
 
 No. Name Sequence Length Annealing 
Temperature 
Idh1R132H P259 Lf_5534 AAGAGTTCTCAGCTCTTTTGGCACGG 26 62 
  P262 Mr_5541 GCATCACGATTCTCTATGC 19 45,1 
Rosa P268 Rosa-Cre1 AAAGTCGCTCTGAGTTGTTAT 21 64 
  P269 Rosa-Cre2 GGAGCGGGAGAAATGGATATG  21 64 
  P270 Rosa-Cre3 CCTGATCCTGGCAATTTCG 19 64 
p53 P307 OIMR 8543 GGTTAAACCCAGCTTGACCA 20 66 
  P308 OIMR 8544 GGAGGCAGAGACAGTTGGAG 20 66 
Cic P636 E8_f AAGAAGGGGATGATGATGTCATTG 24 55,8 
  P637 LoxP2_r GAGCTTCCGTGGCTGAAGC 19 54,8 
  P638 E9_r CTTGTTACCCTCTGGGTCCTCC 22 55,5 
  P404 LoxP3 rv AAACAGTGTCTTCCCTGGTGGAC 23 55,9 
Flp P643 FLP-1 CACTGATATTGTAAGTAGTTTGC 23 43,7 
  P644 FLP-2 CTAGTGCGAAGTAGTGATCAGG 22 48,7 
  P645 FLP-3 CTAGGCCACAGAATTGAAAGATCT 24 52,9 
  P646 FLP-4 GTAGGTGGAAATTCTAGCATCATCC 25 54,3 
Cic RT P714 Cic_RT_E9_10_f GATGACAGCTTTGGCACCAC 20 52,8 
  P715 Cic_RT_E9_10_r AGGTGAAGAGGAGGATGATGG 21 52 
  P716 Cic_RT_E10_11_f CAGCTTCAAGTGGCACCTGC 20 55,7 
  P717 Cic_RT_E10_11_r GAGAAAGGCGAGCTAACCAGG 21 54,8 
Idh1R132H 
KI 
P789 Idh1R132H_KI_rev CTTACTTGGTCCCCATATGCATGAT 25 57,3 
Idh1R132H 
KI WT 
P790 Idh1wt_cond_rev CTTACTTGGTCCCCATATGCATGTC 25 57,6 
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Supplement Figure 1. Long-term cultures lose the ability to produce 2-HG. Idh1R132H 
mutated cells produce 2-HG. After long term cultivation and concomitant loss of Idh1R132H, 
cells lose the ability to produce 2-HG, represented in 2-HG levels below detection limit in 
both supernatant and whole cell lysate. Dashed line indicates detection limit of the assay. 
(n = 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplement Figure 2. Impact of 4-OHT treatment on cell viability. The standard 
concentration of 1µM is not toxic to the cells. Treatment with 10-fold higher 4-OHT 
concentration reduces cell viability to zero. 
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Supplement Figure 3. Genome instability might be caused by upregulated levels of γ-
H2AX in Idh1R132H p53-/- cells. Western blot with antibodies to H2AX and γ-H2AX shows an 
increased expression of γ-H2AX, after induction of the genetic alterations. Data are 
preliminary, as blot reproducibility is very difficult. (n = 1) 
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Supplement Figure 4. Sequencing alignment of the PCR 
product of a cell line that lost the Idh1R132H mutation. Black 
arrows indicate the undetectable region from lox P site 1 until 
Exon 3, which caused the loss of mutant Idh1 protein. 
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